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ABSTRACT

Increased dietary cholesterol promotes the inflammatory response in adipose
tissue and liver, which may contribute to atherosclerosis. We hypothesized that the citrus
flavonoid naringenin would prevent inflammation and atherosclerosis in Ldlr1' mice fed a
cholesterol-enriched, high-fat or low-fat diet. The dyslipidemia and insulin resistance
induced by cholesterol-feeding was markedly attenuated by naringenin. Naringenin
significantly decreased hepatic steatosis, leading to reduced hepatic inflammation and
macrophage infiltration. Furthermore, naringenin prevented diet-induced obesity and
adipocyte hypertrophy, thereby attenuating the inflammatory response in adipose tissue.
Collectively, the improvement in metabolic function by naringenin protected against the
development of complex atherosclerotic lesions. Mice lacking FGF21, a recently
characterized metabolic regulator, were used to determine if FGF21 was essential for
the function of naringenin. Although these studies establish that naringenin does not
require FGF21, they highlight the possibility that naringenin activates other FGF/FGF
receptor molecules. Therefore, naringenin is a promising therapeutic candidate for the
treatment of metabolic disease.
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CHAPTER 1
Thesis Topics Review
1.1 General Introduction
Cardiovascular disease (CVD) is a leading contributor to mortality in developed
nations and by the year 2030, it is projected to surpass infectious disease as the leading
cause of death worldwide (1). Atherosclerosis, the progressive narrowing of medium
sized arteries due to the formation and accumulation of fatty plaque, is the cause of
approximately 50% of CVD deaths in the western world. Several risk factors including
dyslipidemia, hypertension, diabetes and obesity are closely associated with the
development of CVD (2). Other more easily modifiable risk factors include: the
consumption of diets rich in saturated fat and cholesterol, cigarette smoking, and a lack
of exercise (2). Genetics can also determine susceptibility to CVD through modulation of
risk factors. For example, several genetic determinants that impact plasma lipoprotein
size and composition, have been implicated in atherosclerosis (3). Another emerging risk
factor for cardiovascular disease is the metabolic syndrome, a collection of metabolic
disturbances including glucose intolerance, insulin resistance, obesity, dyslipidemia and
hypertension (4,5). The incidence of metabolic syndrome is not only increasing in adults,
but also in children, as evidenced by rising rates of obesity during childhood and
adolescence (6)
With the global increase in CVD and the metabolic syndrome reaching epidemic
proportions, there is an urgent need for therapeutic strategies that will prevent and treat
these diseases. Currently, statin drugs are an effective therapy for preventing mortality
associated with atherosclerosis, due to their targeting of the cholesterol synthesis
pathway, and therefore potent cholesterol-lowering capability (2). However, many
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patients, especially those with the dyslipidemia associated with metabolic syndrome, are
unable to reach their lipid treatment goals on statins alone (7). Also, patients may be
statin intolerant and experience significant side effects (8). Fibrates, another widely
prescribed class of drugs, have been demonstrated to reduce elevated triglyceride (TG)
levels, but have little effect on preventing adverse cardiovascular events (9).
Thiazolidinediones are often used in patients with metabolic syndrome to improve insulin
sensitivity, however they have been shown to promote weight gain and are associated
with off-target-side effects (6). Therefore, the development of new therapeutic
interventions is imperative. This thesis focuses on a citrus flavonoid called naringenin, as
a novel therapeutic alternative for the prevention of processes associated with the
metabolic syndrome and CVD. In mouse models of metabolic dysregulation, naringenin
displays potent lipid-lowering and insulin-sensitizing properties, as well as prevents
inflammation, and atherosclerosis.
1.2 Hepatic Lipoprotein Metabolism
1.2.1 Classes of Lipoproteins
The insolubility of cholesterol and TG in the plasma requires that lipids are
transported through the circulation as lipoproteins. Lipoproteins are spherical molecules
with hydrophobic cores consisting of cholesteryl ester (CE), TG, phospholipids, lipophillic
vitamins and apolipoproteins (3). Lipoproteins are classified based on their size, density
and composition (Table 1-1). The larger lipoproteins, mainly responsible for carrying TG,
are chylomicrons (CM) and very low-density lipoprotein (VLDL) particles. The smaller,
cholesterol-carrying lipoproteins are low-density lipoprotein (LDL) and high-density
lipoprotein (HDL), (3). The synthesis of lipoproteins occurs both in the intestine and liver,
and once secreted in the circulation, they are highly dynamic, undergoing enzymatic
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Table 1-1 Lipoprotein Classification

Phospholipid
Cholesteryl ester
Triglyceride
Free Cholesterol
Structural apolipoprotein
Exchangeable apolipoprotein
Type of
Lipoprotein

% of
lipoprotein
mass

Site of
Origin

Composition

Function

Chylomicrons

83% TG
8% PL 7%
CE, 2%
protein

Intestine
enterocytes
secreted to
lymph

AI, All, AIV, B48,
CM,CHI,E

Delivery of
dietary TG

Very Low
Density
Lipoproteins
(VLDL)

56% TG
20% PL,
15% CE,
9% protein

Liver

B100.C1, C M , c m ,
E

Delivery of
endogenous
TG

Intermediate
Density
Lipoproteins
(IDL)

29% TG,
26% PL,
34% CE,
11 % protein

VLDL
catabolism

B100, C l , C M , c m ,
E

Delivery of
endogenous
TG and CE

Low Density
Lipoproteins
(LDL)

8% TG,
22% PL,
50% CE,
20% protein

VLDL
catabolism

B100

Delivery of
cholesterol

High Density
Lipoproteins
(HDL)

8% TG,
30% PL,
29% CE,
33% protein

Liver and
Intestine
secret
apoA1

AI, AM

T ransport of
Cholesterol
from tissues
to the liver

Adapted from Hegele, R.A. (2009). Nature Rev Genet 10, 109-121
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reactions that transfer different lipid components and apolipoproteins. Lipoprotein
particles can also be delivered to peripheral tissues, and are catabolized by receptormediated endocytosis or by other mechanisms (10).
1.2.2 Exogenous Lipoprotein Metabolism
Dietary lipids must undergo digestion in the stomach prior to absorption.
Cholesterol and TG from the diet form an emulsion in the stomach along with
phospholipids. Lipases secreted from the pancreas into the small intestine hydrolyze TG
molecules to form monoacylglycerols, diacylglycerols and free fatty acids (FFA). The gall
bladder produces bile salts that are secreted into the small intestine via the bile duct,
and combine with FFAs, cholesterol and phospholipids to form mixed micelles (11).
The absorption of lipids into intestinal enterocytes occurs at the brush border
membrane. FFAs enter the enterocyte by passive diffusion or facilitated by specific
transporters including CD36 (12), whereas cholesterol is transported across the brush
border membrane by the Niemann-Pick C1 Like 1 (NPC1L1) transporter (13). NPC1L1
plays an important role in cholesterol and phytosterol absorption and is the target of the
cholesterol absorption inhibitor ezetimibe (13). Approximately 50% of dietary cholesterol
is absorbed in the small intestine (13).
Once inside the enterocyte, FFAs and free cholesterol are re-esterified into TG,
and CE respectively, via enzymes in the endoplasmic reticulum (ER) (3,12).
Chylomicron

assembly

is dependent

on the very

large

hydrophobic protein,

apolipoprotein B48 (apoB48) (11). ApoB48 is produced through mRNA editing of the
transcript coding for apolipoprotein B100 (apoB100) by an enzyme called apoB mRNA
editing complex-1 (APOBEC-1), thereby producing 48% of the full-length apoB100
molecule (14,15). In contrast to humans who only express APOBEC-1 in the intestine,
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mice express APOBEC-1 in both the liver and intestine, allowing both apoB100 and
apoB48 to be produced by the liver (16).
Microsomal triglyceride transfer protein (MTP), transfers mostly TG (80-90%),
some CE, and phospholipids onto the apoB48 molecule in the ER. The newly
synthesized pre-chylomicrons bud from the ER membrane in vesicles, which are
transported to the Golgi apparatus for further processing and secretion into the lymphatic
system, followed by entry into the plasma circulation via the vena cava (11). Other
apolipoproteins (apoA1, apoAIV, apoE and apoCI-lll) bind to chylomicrons during their
modification in the lymph and plasma (3), and are involved in subsequent particle
catabolism (Figure 1-1).
Chylomicron hydrolysis occurs via lipoprotein lipase (LPL), an enzyme located on
the surface of the vascular endothelium of capillaries that perfuse peripheral tissues,
including

adipose

tissue

and

skeletal

muscle.

Bound

to

heparin

sulphate

glycosaminoglycans on the cell surface, LPL is activated by the apoCII molecule present
within the chylomicron particle. This apoCII-LPL interaction facilitates TG hydrolysis and
fatty acid (FA) uptake into peripheral cells. As the TG-rich core of the chylomicron
particle is depleted, the cholesterol-rich chylomicron remnant particle is cleared from the
circulation by the liver via binding of the apoE protein to the low-density lipoprotein
receptor (LDLR) or the LDLR-related protein 1 (3,17).
1.2.3 Endogenous Lipoprotein Metabolism
1.2.3.1 Secretion of ApoBIOO-Containing Lipoproteins
The liver plays a crucial role in lipid biosynthesis and lipoprotein secretion, and is
therefore central to endogenous lipoprotein metabolism (Figure 1-1). TG and CE from
hepatic neutral lipid stores or from endogenous synthesis are packaged into VLDL for
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Capillaries

kFFA

Capillaries

* Adipose/muscle ◄
------- FFA

Figure 1-1. Endogenous and Exogenous Lipoprotein Metabolism
In the intestine, dietary TG and cholesterol are secreted as chylomicrons initially into the
lymphatics and subsequently into the blood stream. FFA are delivered to peripheral tissues
following lipolysis of TG by LPL, resulting in the formation of CE-rich remnant particles that are
subsequently taken up by the liver through the LDLR-mediated endocytosis. In endogenous
lipoprotein metabolism, the liver secretes TG-rich VLDL particles, which also undergo
hydrolysis by LPL in the periphery. The subsequent CE-rich particles, IDL and LDL can also be
cleared by the LDLR in the liver. Cholesterol from peripheral tissues is effluxed to HDL, which is
also taken up by the liver.
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delivery to peripheral tissues (14). Each VLDL particle consists of one apoB100
molecule, as well as several other apolipoproteins including apoE and apoCI-lll (3).
The human APOB gene is located on chromosome 2, consists of 4,536 amino
acids and is translated into a large protein, approximately 517-550 kDa in mass (18).
The apoB100 protein is co-translationally inserted into the ER lumen where various
chaperone proteins ensure that the apoB100 molecule is folded properly. However,
should misfolding occur, or insufficient lipid is transferred, apoB100 is polyubiquitinated
and shuttled to the proteasome for degradation (15). In a similar fashion to chylomicrons
biogenesis, the chaperone protein MTP plays a critical role in transferring lipids onto the
apoB100 molecule as it is transported into the ER, forming a pre-VLDL particle (15).
Patients with abetalipoproteinemia who have a mutation in the MTP gene, have no
detectible levels of apoB100 in their plasma (19). The preference for lipid transfer by
MTP to apoB100 is TG > CE > diacylglycerol > phospholipid (20). The TG substrates
used for VLDL assembly are either derived from de novo FA synthesis, or from TG
within cytoplasmic storage droplets in (14). The lipid-loaded particle exits the ER by
forming COPII-coated vesicles (21), and undergoes further maturation by trafficking to
the Golgi (14) through an MTP-independent mechanism (22), after which it is secreted
into the circulation (Figure 1-1).
1.2.3.2 Cellular uptake and Clearance of ApoBIOO-containing lipoproteins
Once secreted into the plasma, VLDL particles undergo lipolysis by apoCIIactivated, cell-surface bound LPL in peripheral tissues, in a manner similar to
chylomicron lipolysis. The TG-rich core of VLDL is depleted allowing the formation of
VLDL remnant particles. The enzymatic action of the cholesterol ester transfer protein
(CETP), allows VLDL remnants to acquire increasing amounts of CE from HDL
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molecules in circulation, in exchange for TG. Rodents however, do not express CETP,
and therefore carry most of their cholesterol in HDL particles (23). At this stage, the
cholesterol-rich remnant particle is referred to as an intermediate density lipoprotein
(IDL) that is smaller in size and density (24). The enrichment of CE and the loss of apoE
in the IDL molecule, and lipolytic modification by hepatic triglyceride lipase (HTGL),
signify either LDLR-mediated hepatic clearance or the formation of the LDL particle. This
CE-rich LDL particle carries most of the cholesterol in the plasma and contains one
molecule of apoB100, allowing it to be cleared in the liver by the LDLR, a protein
synthesized in the ER (24).
1.2.3.3 The LDL receptor (LDLR)
The LDLR is a cell-surface, transmembrane glycoprotein receptor responsible for
the clearance of both apoB and apoE-containing lipoproteins including VLDL, IDL, and
LDL. The LDLR contains five domains, including an LDLR type A repeat domain that is
responsible for ligand binding, an epidermal growth factor (EGF) receptor homology
domain, an O-linked glycosylation domain, the hydrophobic transmembrane domain and
a cytoplasmic domain (25,26). The clearance of lipoproteins by the LDLR involves
receptor-mediated endocytosis, whereby clatharin-coated pits pinch off from the surface
of the cell membrane. These pits fuse with endosomes that have a slightly acidic pH,
allowing the LDL molecule to dissociate from its receptor and undergo degradation by
hydrolases (27). Following separation from its ligand, the LDLR is either targeted for
lysosomal degradation or recycled to the surface of the cell for re-use, making one round
trip from the cell surface to the interior approximately every 10 minutes (28).
Mutations in the LDLR gene causes familial hypercholesterolemia (FH), an
autosomal dominant disease characterized by elevated plasma cholesterol levels,
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tendon xanthomas and an increased risk of developing cardiovascular disease (27).
Over 1100 mutations in the LDLR gene have been identified in FH patients (28), and
these mutations can affect many aspects of the receptor’s life cycle, including ligand
binding, receptor internalization, recycling to the cell surface and even synthesis in the
ER (17).
The promoter region of the LDLR contains a sterol-response element (SRE), and
is therefore regulated by the sterol regulatory element binding proteins (SREBPs) (see
section 1.3.3.1). Increased internalization of LDL-cholesterol by the LDLR results in
reduced 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase-mediated cholesterol
biogenesis, increased cholesterol esterification for storage as neutral lipid droplets, and
reduced expression of the LDLR via SREBP regulation (29).
1.2.3.4 Reverse Cholesterol Transport (RCT)
RCT involves the transport of cholesterol from peripheral tissues back to the liver
for disposal into the feces (Figure 1-1). The main lipoprotein involved in RCT is HDL,
which accepts cholesterol from the plasma membranes of peripheral cells (23). Various
subclasses of HDL participate in RCT including pre (3 HDL, HDL3 and HDL2. The
discoidal pre [3 HDL molecule is secreted from the liver and contains apoA1, the main
lipoprotein associated with HDL. Pre (3 HDL accepts free cholesterol from the plasma
membrane via the ATP-binding cassette transporter A1 (ABCA1), which binds to apoA1
within the pre (3 HDL molecule (23). ABCA1 is under direct control of the liver X receptor
(LXR), and is upregulated in response to increased cellular cholesterol (28).
In the plasma, an enzyme associated with HDL called lecithin:cholesterol acyl
transferase (LCAT), catalyzes the formation of CE from free cholesterol (FC) and
phophatidylcholine within the core of the lipoprotein. This forms a spherical HDL particle
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called HDL3, which continues to accept ABCA1-mediated cholesterol from peripheral
membranes (30). Finally, as the CE-rich core of the HDL particle becomes larger, it is
called a mature HDL2 particle. HDL2, transfers CE to apoB-containing lipoproteins in
exchange for TG or delivers CE to the liver via the binding of HDL to the scavenger
receptor-B1 (SR-B1). In the liver, the newly acquired CE is hydrolyzed to FC and can be
used by the hepatocyte for bile acid and membrane synthesis, secreted into bile, stored
in neutral lipid droplets as CE or it can be packaged into VLDL particles for re-secretion
into plasma (23).
1.2.4 Atherogenic Lipoproteins
Elevated circulating lipid levels are a risk factor for the development of
atherosclerosis. Specifically, elevated concentrations of TG, high levels of small dense
LDL particles, and low concentrations HDL-cholesterol are associated with atherogenic
dyslipidemia (31).
The most atherogenic lipoprotein is LDL, as it is cholesterol-rich and small
enough to penetrate the endothelium of the artery wall (32). Elevated LDL particles can
result from a defect in lipoprotein clearance, such as in patients with FH (32), or they can
also occur in familial defective apoB, where there is a mutation in the apoB protein (33).
Statins are the most effective form of cholesterol lowering in patients with
hypercholesterolemia, and will lower LDL-cholesterol by 30-60% mainly by upregulation
of LDLR-mediated hepatic clearance (32).
In addition to LDL, an increase in the size or number of TG-rich VLDL particles,
which also contain cholesteryl ester, can be a risk factor for atherosclerosis (32).
Increases in FFA flux from adipose tissue to the liver during states of obesity results in
the accumulation of hepatic TG, and the subsequent overproduction of TG-rich VLDL
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particles, thereby contributing to hypertriglyceridemia. As the VLDL-TG pool increases,
LDL particles are enriched in TG allowing subsequent hydrolysis and the formation of
smaller, denser, LDL particles, that can more easily penetrate the artery wall (34).
1.3 Fatty Acid and Cholesterol Metabolism
1.3.1 Fatty Acid and Triglyceride Synthesis
De novo FA synthesis in the liver begins in the cytoplasm using the 2 carbon
molecule acetyl co-enzyme A (acetyl-CoA), a product from the catabolism of glucose. FA
synthesis is initiated when the metabolic requirement for fuel is met, therefore preventing
FA oxidation and increasing FA storage as TG. The synthesis of FAs occurs via two
main enzymes. Acetyl Co-A carboxylase (ACC) performs the first committed step in FA
synthesis and coverts acetyl-CoA to malonyl-CoA. Fatty acid synthase (FAS), a
multienzyme complex, performs the remaining four enzymatic reactions to produce the
saturated FA palmitate, which contains 16 carbons. Saturated FAs can undergo
elongation by FA elongase, and desaturation by stearoyl-CoA desaturase (SCD), to
produce a variety of longer mono-unsaturated FAs (35).
FAs from the hydrolysis of TG within circulating chylomicron particles, adipose
tissue lipolysis, or de novo synthesis, can be packaged into TG molecules by entering
the glycerolipid synthetic pathway. TG synthesis occurs in the ER membrane and
involves four steps, which package three FA molecules onto a glycerol backbone (36).
FAs must be activated in order to participate in TG synthesis, and this involves the
addition of coenzyme A via acyl-CoA synthetase (ACS) thereby forming fatty acyl-CoA.
Two Fatty acyl-CoA molecules are esterified to glycerol-3-phosphate forming 1,2diacylglcerol phosphate, also known as phosphatidic acid. The phosphate group is then
removed from phosphatidic acid which forms diacylglycerol (DAG). The final step is
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catalyzed by DAG acyltransferase (DGAT), which adds another FA to DAG forming the
complete TG molecule. In the liver, TG can either be stored in neutral lipid droplets for
use by the cell during the fasted state, or it can be packaged into VLDL particles for
transport to peripheral tissues (37).
Dietary carbohydrates can also contribute to de novo lipogenesis. The main
sugars in the diet are glucose, fructose, sucrose (glucose plus fructose disaccharide),
lactose and maltose (glucose disaccharide) (38). However, increased fructose
consumption has been linked to obesity and type 2 diabetes (38). After absorption,
fructose travels via the portal vein to the liver, which is the main site of fructose
metabolism. In the liver, fructose is phosphorylated by fructokinase, resulting in the
production of fructose-1-phosphate. Frucose-1-phosphate has the ability to bypass the
rate-limiting enzyme in glycolysis, phosphofructokinase, therefore avoiding regulation by
insulin (38). This allows fructose trioses to be used for the production of glyceraldehydes
or acetyl-CoA, which contribute to the production of TG. Therefore, unlike glucose
whose uptake and synthesis is regulated by phosphofructokinase, fructose can serve as
an unregulated source of substrates for de novo lipogenesis and can contribute to the
production of VLDL particles (39).
1.3.2 Cholesterol Synthesis and Esterification
Cholesterol is an important molecule required for the formation of steroids,
oxysterols, bile acids and vitamins, as well as for the maintenance of membrane fluidity.
It is synthesized in peripheral tissues and the liver from the precursor acetyl-CoA to
produce HMG-CoA. A rate-limiting enzyme for cholesterol biosynthesis and the
therapeutic target for the statin class of drugs is HMG-CoA reductase, an ER membrane
protein that catalyzes the conversion of HMG-CoA to mevalonate. Through a series of
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phosphorylation and condensation reactions, mevalonate is converted to squalene,
which undergoes cyclization to form lanosterol. Finally, after another 19 reactions,
lanosterol is converted to cholesterol (40).
Excess cellular free cholesterol is esterified into CE using the protein acylCoenzyme A: cholesterol acyl transferase (ACAT), which resides in the ER. Hepatic CE
can be stored in intracellular lipid droplets or it can be packaged onto the apoB100
molecule for the production of VLDL (41). An SRE is located in the promoter of the
HMG-CoA reductase gene, allowing it to be under transcriptional control of the SREBP-2
(see section 1.3.3.1) (42).
1.3.3 Regulation of TG and Cholesterol Synthesis
De novo lipogenesis is controlled by a variety of transcription factors induced by
hormonal changes and alterations in dietary nutrients.
1.3.3.1 Sterol Regulatory Element Binding Proteins (SREBPs)
SREBPs are a family of membrane-bound transcription factors that regulate
genes involved in FA, TG and cholesterol metabolism. Structurally SREBPs are a
member of the basic helix-loop-helix-leucine zipper (bHLH-zip) family of transcription
factors, and are synthesized as inactive precursors bound to the ER membrane. SREBP
must undergo proteolytic processing in order to enter the nucleus and act as a
transcription factor. Once synthesized and inserted into the ER membrane, SREBP
binds to the SREBP cleaving-activating protein (SCAP) (43). When cellular cholesterol
levels are low, the SCAP/SREBP complex binds to coat protein complex II (COPII)
proteins located within COPII-coated vesicles. These vesicles bud from the ER
membrane and complex to the Golgi apparatus where two proteases, site-1 protease
(S1P), and site-2 protease (S2P), act consecutively to cleave the bHLH-zip DNA
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binding-domain from SREBP. The bHLH-zip domain is then free to enter the nucleus,
where it binds to SREs in the promoter of target genes. When the sterol-sensing domain
of SCAP senses either elevated cellular cholesterol or oxysterol, SCAP binds to one of
two ER anchor proteins insulin signaling protein (Insig) -1 or -2, preventing SCAP from
associating with to COPII-coated vesicles. Therefore, SREBP cannot undergo proteolytic
processing in the Golgi and the bHLH-zip domain of SREBP cannot regulate gene
transcription (44).
There are three isoforms of SREBPs that are encoded on two chromosomes.
SREBP-1a and SREBP-1c are produced from the same gene via alternative splicing of
exon 1 on chromosome 17, while SREBP-2 is found on a separate chromosome.
SREBP-1a and SREBP-2 are ubiquitously expressed and are involved in regulating
lipogenesis. In particular, SREBP-2 regulates the cholesterol biosynthetic enzymes such
as HMG-CoA reductase and the LDLR (43). Hepatic over expression of SREBP-2 in
mice increases Hmg-CoA reductase expression approximately 75-fold and markedly
enhances the development hepatic steatosis (45), whereas knocking out Srebp-2 in the
liver is embryonic lethal (43).
SREBP-lc, which is predominately expressed in the liver, controls genes
involved in FA synthesis, including FAS, ACC, and SCD-1 (46). Transgenic mice over
expressing SREBP-1c in the liver have significantly increased FA synthesis and hepatic
TG levels without impairments in cholesterol synthetic genes (47). In contrast, mice that
lack the Srebpl gene, encoding both SREBP-1a and -1c, have reduced expression of
FAS and ACC resulting in reduced FA synthesis (48).
There are several factors that transcriptionally regulate SREBPs, including
insulin, glucagon and LXR. The normal physiological effect of insulin includes the
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stimulation of glycolysis and the upregulation of lipogenic genes including FAS, ACC and
SCD-1. It has been shown that SREBP-1c is an important factor for insulin-mediated
lipogenesis, as administration of nuclear SREBP-1c induces de novo lipogenesis, similar
to the effects of insulin alone (49). In the rat SREBP-1c promoter, insulin regulates the
SREBP-1c gene via four transcription-factor binding elements including, LXRa, the
specificity protein 1- binding element, an NF-Y element and SREBP-1c itself (50,51).
Insulin also participates in post-transcriptional processing of SREBPs in the liver
via regulation of Insig, which prevents the SCAP/SREBP complex from leaving the ER
(44). The lnsig-1 protein is induced by insulin, while lnsig-2a is suppressed by insulin. In
order to counter-act insulin, glucagon reduces the abundance of SREBP, as primary
hepatocytes incubated with glucagon have decreased expression of SREBP-1c mRNA
and target lipogenic genes (52,53).
1.3.3.2 Liver X Receptor (LXR)
LXR is a nuclear receptor and member of the ligand-activated transcription
factors that plays an important role in regulating cholesterol metabolism. However,
cholesterol itself is not an activator of LXR. Instead, oxysterols are the natural ligands for
LXR, including 24(S),25-epoxy cholesterol, the most potent LXR activator (54). Two
isoforms, LXRa and LXRp are encoded on two different chromosomes and differ in
tissue localization. LXRa is predominantly expressed in the liver, small intestine,
adipose, kidney and in macrophages, while LXR(3 is ubiquitously expressed (54). LXR
heterodimerizes with different isoforms of the retinoid X receptor (RXR), including RXRa,
RXRp, or RXRy, and binds to LXR-response elements (LXRE) in the promoter of target
genes.
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LXR acts a cholesterol sensor, as increased cellular oxysterol levels results in
the regulation of genes that prevent cholesterol overload in the cell. In order to promote
the elimination of cholesterol from the body, LXR increases the expression of cholesterol
P450 7a-hydroxylase (CYP7A1), the rate-limiting gene involved in bile acid synthesis
(55). Another mechanism through which LXR regulates the delivery of cholesterol into
the bile is through upregulation of ATP-binding cassette transporter G5 and G8 (ABCG5
and ABCG8), which transport cholesterol from hepatocytes to bile canaliculi or from
enterocytes into the lumen of the small intestine (56). LXR also mediates RCT by
increasing ABCA1 and ABCG1, which are responsible for transporting cholesterol to
lipid-poor apoA1 and HDL, respectively (56).
LXR is also a known regulator of SREBP-1c. Repa et al. demonstrated that an
LXRE is located in the 5’-flanking region of the mouse Srebp-1c gene. Furthermore,
feeding wildtype mice a cholesterol-rich diet has been shown to significantly upregulate
Srebp-1 mRNA. In contrast, mice deficient in LXRa/p could not induce Srebp-1
expression in response to cholesterol-feeding. (57).
1.3.4 Fatty Acid Oxidation
FA oxidation is a crucial component of energy homeostasis in the liver, heart and
skeletal muscle, because FAs can be used for the production of energy in the fasted
state when glucose levels are low. Short-, medium-, and long-chain FAs undergo
oxidation in the mitochondria, which is the main site of p-oxidation (58). The rate-limiting
enzyme for mitochondrial p-oxidation, carnitine palmitoyltransferase 1 (CPU), is located
on the outer mitochondrial membrane. Due to the impermeability of the mitochondria to
acyl-CoA, CPT1 converts the acyl-CoA into an acylcarnitine allowing it to cross the inner
mitochondrial membrane. The acyl-CoA undergoes further oxidation by membrane
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bound enzymes to produce acetyl-CoA, which is a substrate for the production of ATP in
the citric acid cycle. Two isoforms of CPT exist; CPT1a, which is expressed in the liver,
brain, kidney and pancreas, and CPT1(3, which is expressed in cardiac and skeletal
muscle (58,59).
FA flux to the mitochondria is regulated by malonyl-CoA, which is produced from
acetyl-CoA by ACC during the synthesis of FFA. Malonyl-CoA is a natural inhibitor of
CPT 1 such that during the fed state, malonyl-CoA levels increase and CPT 1 is inhibited,
which shunts FFA towards storage as TG (60). Mice with liver-specific over expression
of CPT-1a are prevented from high-fat diet induced hepatic steatosis, highlighting the
importance of CPT-1a in the regulation of FA oxidation (61). (3-oxidation can also occur
in the peroxisome, which is the primary site of metabolism of very-long chain FAs. A key
step in this pathway is the oxidation of very-long chain FFAs to their trans-2-enol-CoAs
by the enzyme fatty acyl-CoA oxidase 1 (ACOX-1) (62).
1.3.5 Regulation of Fatty Acid Oxidation
1.3.5.1 Peroxisome Proliferator-Activated Receptor a(PPARa)
Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear
receptors that act as ligand-dependent transcription factors. PPARs heterodimerize with
RXR and bind to PPAR response elements (PPREs) in the promoter of target genes
(63). There are three isoforms of PPARs including PPARa, PPAR8, and PPARy, all of
which are involved in lipid transport and metabolism. PPARa primarily regulates FA
oxidation and is therefore expressed in metabolically active tissues including the liver,
heart, brown adipose tissue and muscle (63,64).
Endogenous PPARa ligands include saturated and polyunsaturated FAs,
however PPARa can also be activated by synthetic ligands including a class of drugs
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called fibrates, known for their hypolldemic properties. PPARa-regulated genes include
CPT-1a and ACOX-1. The importance of PPARa in regulating these key (3-oxidation
enzymes is apparent in PPARa-null mice, which exhibit hepatic steatosis and
hyperlipidemia, due to an inability to upregulate hepatic Cpt-1aand Acox-1 (65,66).
1.3.5.2 PPAR-y Co-Activator-1 a (PGC-1 a)
In order to facilitate gene transcription, a variety of co-activator molecules exist
that interact with transcription factors and mediate their localization to the promoter
regions of genes (67). A specific co-activator involved in energy homeostasis and
metabolism is PGC-1 a. Through the LXXLL motifs in its N-terminus, PGC-1 a interacts
with various nuclear receptors including PPARs and RXRa, facilitating gene transcription
(68). PGC-1 a is upregulated in response to fasting, to promote gluconeogenesis and the
oxidation of FA for energy. In particular, PGC-1 a is a co-activator for PPARa, resulting in
upregulation of hepatic FA-oxidation (68). PGC-1 a-null mice exhibit a delayed response
to fasting, are hypoglycemic and develop significant hepatic steatosis (69,70). PGC-1 a is
also known to play an important role in mitochondrial biogenesis, thereby increasing the
oxidative capacity of muscle cells (71).
1.3.5.3 Fibroblast Growth Factor 21 (FGF21)
A recently identified factor involved in the regulation of fatty acid oxidation by
PPARa is FGF21. FGF21 is a member of the endocrine subfamily of FGFs because it
lacks the conventional heparin-binding domain, and therefore has low affinity for cellsurface FGF receptors (FGFR), allowing it to act in an “endocrine-like” manner and act
on distal tissues (72) (Figure 1-2). In mice, FGF21 is expressed and secreted from the
liver, adipose tissue, pancreas and muscle (72). The tissue-specific activity of FGF21 is
mediated by its transmembrane co-receptor (3-Klotho, which is expressed in the
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Figure 1-2. Role of FGF21 in hepatic FA oxidation and ketogenesis. PPARa
belongs to a family of ligand dependant transcription factors that interact as obligate
heterodimers with RXR, and bind to PPAR response element (PPRE) within the
promoter regions of target genes. The FGF21 gene contains a PPRE within its promoter
region, and is therefore synthesized and secreted upon ligand activation of PPARa.
PPARa-independent synthesis and secretion of FGF21 also occurs by an unknown
mechanism. Secretion of FGF21 can function as an endocrine factor or as a
paracrine/autocrine factor by binding to its cell-surface FGF receptor. p-Klotho, an FGF
co-receptor, is required for the initiation of FGF21-mediated signal transduction through
PI3K and/or MAPKerk signaling to upregulate genes involved in FA oxidation and
ketogenesis, via PGC-1a.
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pancreas, adipose tissue and liver (73,74). Upon binding of FGF21 to the FGFR/(3Klotho complex, a signaling cascade is initiated resulting in the phosphorylation of the
FGFR substrate 2 (FRS 2) and eventual downstream phosphorylation of extracellular
related kinase 1/2 (ERK1/2) (75).
FGF21 is regulated by PPARoc, as the PPARa ligands unsaturated FAs and
fenofibrate, have been shown to induce FGF21 expression in vitro (76). Furthermore
PPARa-null mice have significantly reduced expression of hepatic Fgf21 (76). Similar to
PGC-lcc, FGF21 is induced in response to fasting. This is evident in mice lacking FGF21
that exhibit impaired upregulation of Pgc- 1a expression in response to a prolonged fast,
highlighting role of FGF21-mediated regulation of PGC-1a (77). In addition, FGF21deficient mice develop significant hepatic steatosis and have impaired glucose control
when fed a ketogenic diet (78). The importance of FGF21 as a metabolic regulator was
further demonstrated when the administration of exogenous recombinant FGF21 protein
to mice, reversed diet-induced obesity, hepatic steatosis, and hyperinsulinemia (79).
1.4 Hepatic Steatosis and Inflammation
Excessive hepatic lipid accumulation can induce non-alcoholic fatty liver disease
(NAFLD), which is a spectrum of disorders that range from hepatic steatosis, to
steatohepatitis, to cirrhosis of the liver. NAFLD can arise through several mechanisms,
including increased availability of lipids from the diet, as excess carbohydrate, FFA and
cholesterol intake are all associated with hepatic steatosis and inflammation (80,81).
NAFLD is considered to be a “multi-hit” process and can occur through increased
delivery of FFAs to the liver during insulin resistance (see section 1.5.2). In the first “hit”,
an increase in FFA flux from adipose tissue to the liver disrupts the normal hepatocyte
equilibrium such that FFA uptake and esterification to TG overwhelms the liver’s ability
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to oxidize FA. When TG synthesis is greater than the rate of VLDL synthesis and
secretion, TG accumulation occurs resulting in hepatic steatosis (82,83).
The second “hit” involves the progression from hepatic steatosis to non-alcoholic
steatohepatitis (NASH); a state of oxidative stress, hepatic inflammation and hepatocyte
apoptosis (83). During NASH, FA can become hepatotoxic, stimulating the secretion of
tumor necrosis factor a (TNFa) from hepatocytes. TNFa can activate signaling pathways
that result in hepatocyte death and the accumulation of inflammatory cells in the liver,
therefore interfering with insulin signaling, and contributing to insulin resistance (84,85).
TNFa can also contribute to the development of dyslipidemia, as the administration of
TNFa to Syrian golden hamsters can stimulate hepatic production of apoB100, thereby
increasing plasma VLDL (86).
However, it is not just hepatocytes that can contribute to hepatic steatosis and
inflammation. Kupffer cells (KC) are resident macrophages in the liver that are derived
from circulating monocytes. KCs are responsible for performing various functions
including phagocytosis, antigen presentation, and the production of inflammatory
cytokines (87). Recently, it has been demonstrated that TNFa secretion from KCs has
detrimental effects on hepatic lipid metabolism in hepatocytes, and contributes to the
development of hepatic steatosis in rats fed high-carbohydrate or high-fat diets.
Furthermore when KCs are depleted from the liver of these animals, the development of
fatty liver and insulin resistance is blunted (88). Stienstra et at. have also established
that interleukin-1 p (IL-1 (3) production from KCs in mice suppresses PPARcr activity,
contributing to hepatic steatosis (89).
1.4.1 Hepatic Inflammation and Dietary Cholesterol
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Although the accumulation of large amounts of TG in the liver is a driving force of
hepatic inflammation, it has been shown that dietary cholesterol may also contribute to
the development of steatohepatitis (90-93). In Ldlrv' mice the addition of cholesterol to a
high-fat diet is sufficient to cause an inflammatory response in the liver, as indicated by
increased expression of inflammatory cytokines and macrophage markers, therefore
promoting the progression of hepatic steatosis to hepatic inflammation (91). Recently,
Subramanian et al. demonstrated that upon the addition of 0.15% cholesterol to a highfat, high-carbohydrate diet, inflammatory cytokine expression and the presence of
macrophage galactose-specific lectin-2 (MAC-2) -stained macrophages were increased
in the liver (94). The expression of the cytokine monocyte chemoattractant protein-1
(MCP-1) was significantly upregulated by 16 weeks of feeding a high-cholesterol diet in
LdlrA mice, which was associated with increased hepatic lipid accumulation (95).
Feeding cholesterol-rich diets to various other mouse models also demonstrate an
increased susceptibility to hepatic steatosis and acute hepatic inflammation, resulting in
elevated plasma levels of inflammatory markers (96,97). Furthermore, Mari et al.
reported that free cholesterol enrichment of the mitochondrial membrane within
hepatocytes, sensitizes cells to TNFa- and FA-mediated apoptotic and inflammatory
signaling pathways by depletion of mitochondrial glutathione levels (98). Collectively
these studies demonstrate the role of dietary cholesterol in mediating the metabolic
changes associated with hepatic steatosis and inflammation.
1.5 Insulin
1.5.1 Insulin Function and Signaling
Insulin is an essential peptide hormone secreted from pancreatic (3-cells that is
involved in controlling glucose homeostasis, tissue development and growth (99). In
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response to the ingestion of a meal, increased circulating glucose and amino acids
results in insulin secretion, and the subsequent synthesis of lipids, glycogen and proteins
(99) . Insulin has a wide range of effects in the liver, muscle, and adipose tissue. In the
liver, insulin increases hepatic lipogenesis, while at the same time suppresses hepatic
VLDL production and gluconeogenesis. In muscle, insulin stimulates glucose uptake for
conversion to glycogen, and prevents the breakdown of protein. In adipose tissue,
insulin increases LPL-mediated hydrolysis of lipoproteins and inhibits hormone sensitive
lipase (HSL)-mediated lipolysis of cellular TG, thereby promoting FFA storage as TG
( 100) .

Insulin’s effects are mediated through the insulin receptor, a heterodimeric
protein in the plasma membrane. The insulin receptor consists of two a-subunits that
bind to the insulin molecule and two [3-subunits that mediate intracellular signaling (101).
The binding of insulin to the a-subunits activates the transphosphorylation of kinase
domains in the (3-subunits, resulting in phosphorylation of insulin receptor substrates
(IRS). This initiates a complex cascade of events that results in the activation of two
important signaling pathways, mitogen-activated protein kinase (MAPK) pathway and the
phosphatidylinositol 3-kinase (PI3-kinase) pathway (101). The MAPK pathway is
associated with the proliferative effects of insulin including cell growth and differentiation
(101). Insulin-dependent MAPK signaling has also been shown to be involved in
inhibiting the expression of MTP, therefore reducing the production of apoB100 particles
from hepatocytes (102,103).
The PI3-kinase branch of the insulin signaling cascade is involved mediating the
metabolic effects of insulin and activates Akt and protein kinase C (PKC). Akt has
numerous intracellular targets including glycogen synthase kinase 3 (GSK3). Inactivation
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of GSK3 by Akt, results in the activation of glycogen synthase and subsequent
conversion of glucose to glycogen (99). Akt also phosphorylâtes the transcription factor
forkhead box protein 01 (Fox01), resulting in nuclear exclusion of Fox01 and a
reduction in the transcription of gluconeogenic target genes, phosphoenolpyruvate
carboxykinase (PEPCK) and glucose 6-phosphatase (104). Phosphorylation of Akt also
results in downstream activation of mammalian target of rapamycin complex 1
'(mTORCI), which is required for the insulin-stimulated activation of SREBP-1c, thereby
increasing lipogenesis. Therefore, the bifurcation of the insulin signaling pathway at Akt
results in activation of the gluconeogenic and lipogenic pathways (105).
The PI3-kinase pathway has also been implicated in regulating the insulin
dependent glucose transporter GLUT-4, which is found in insulin-sensitive tissues such
as muscle and adipose tissue. Activation of insulin signaling results in the rapid
translocation of intracellular GLUT-4 to the plasma membrane, thereby facilitating
glucose uptake (100).
1.5.2 Insulin Resistance
Insulin resistance occurs when normal concentrations of insulin in the plasma are
no longer able to mediate anabolic effects on glucose metabolism. Insulin resistance is a
central component of the metabolic syndrome and is closely associated with obesity and
dyslipidemia (6,101). The co-morbidity of these metabolic abnormalities is associated
with increased risk of cardiovascular disease (5). Furthermore, insulin resistance is a
defining characteristic of type 2 diabetes; a disease of fasting hyperglycemia due to
defective insulin secretion from pancreatic p-cells and/or reduced insulin sensitivity in the
liver and peripheral tissues. Although the primary defect in type 2 diabetes is unknown,
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many environmental and genetic factors contribute to the pathogenesis of the disease
(106).
1.5.2.1 Hepatic Insulin Resistance
The development of the liver insulin receptor knockout (LIRKO) mouse helped to
characterize hepatic insulin resistance. These mice have a complete absence of the
hepatic insulin receptor, and therefore exhibit fasting hyperglycemia, due to the impaired
ability of insulin to suppress hepatic glucose production. Hyperinsulinemia develops in
this model as the pancreatic (3-cells undergo expansion to try to compensate for
increased glucose levels. LIRKO mice also demonstrate impaired TG secretion, due to
the absence of insulin-mediated SREBPIc-stimulated FA synthesis from the liver (107).
Therefore, hepatic insulin resistance is more severe than total hepatic insulin
resistance (108). In insulin resistant ob/ob mice, FoxOI-mediated suppression of
gluconeogenesis is impaired, resulting in increased glucose production (109). At the
same time, the mTORCI pathway that regulates SREBP-1c-mediated lipogenesis
remains sensitive to insulin, resulting in FA synthesis, hepatic TG accumulation and
increased secretion of VLDL (105,109). Therefore, selective hepatic insulin resistance
results in hyperinsulinemia, hyperglycemia and dyslipidemia, which are characteristic of
type 2 diabetes.
Dyslipidemia is associated with insulin resistance and is a consequence of
increased hepatic VLDL secretion due to a failure of insulin to upregulate the LDLR
(110). The increased delivery of FFA from expanded adipose tissue stores in obesity,
along with the maintained sensitivity of the SREBP-1c-lipogenic pathway results in
increased hepatic lipid accumulation, and increased substrate availability for the
production of TG-rich VLDL particles (110). Furthermore, in insulin-resistant, fructose-fed
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hamsters, impaired insulin signaling, including reduced IRS, PI3-kinase and Akt
activation, was associated with reduced apoB100 degradation and subsequent
overproduction of hepatic VLDL (111). Therefore, insulin resistance is a significant
contributor to the development of hypertriglyceridemia.
1.5.2.2 Insulin Resistance in Peripheral Tissues - Adipose Tissue and Muscle
Obesity, characterized by adipocyte expansion, is a contributor to insulin
resistant states. Specifically, abdominal or visceral adipose tissue is thought to
contribute more to insulin resistance than subcutaneous adipose tissue (112). During
obesity, insulin cannot inhibit HSL-mediated lipolysis due to impaired insulin signaling,
resulting in enhanced delivery of FFA to the liver, thereby contributing to hepatic insulin
resistance (112).
Adipose tissue expansion is also associated with enhanced secretion of
adipokines including leptin, and a variety of inflammatory cytokines. Leptin is a satiety
factor produced by adipocytes that acts on the hypothalamus to reduce food intake
(113). Leptin deficient ob/ob mice develop marked insulin resistance and the re
administration of leptin rapidly reduces glucose and insulin levels, independent of
changes in food intake or body weight (114), demonstrating the role of adipose tissue
secreted factors on maintaining normal glucose homeostasis.
Skeletal muscle is also an important regulator of glucose homeostasis and
disposes of 70-90% of blood glucose after the ingestion of meal (101). Therefore, the
development of insulin resistance in muscle is a significant contributor to the onset of
type 2 diabetes. Defects in insulin receptor signaling have been demonstrated to
participate in the development of insulin resistance. During insulin resistance, the
capacity of muscle to utilize glucose and FA is impaired (115). In particular, the buildup
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of FA metabolites diacylglycerol and ceramide (116), can interfere with insulin signaling
by activating inhibitory serine kinases which can directly phosphorylate the insulin
receptor on serine residues and inhibit its activity (115). Some patients with type 2
diabetes have a functional defect in the insulin-induced tyrosine phosphorylation of IRS1 (117). Furthermore, insulin-resistant ob/ob mice have reduced activity of insulin
receptor kinase and insulin-stimulated PI3-kinase in muscle (118). An important feature
of insulin resistance in muscle is reduced glucose uptake. In the skeletal muscle of
patients with type 2 diabetes, the abundance of cell-surface GLUT-4 transporters is
reduced, resulting in decreased insulin-stimulated glucose uptake (117). Although the
precise mechanism for the reduction in glucose uptake is unknown, in vitro experiments
using the PI3-kinase inhibitor wortmannin demonstrated reduced GLUT-4 translocation
to the plasma membrane, therefore implicating defective insulin signaling through the
PI3-kinase pathway
1.6 Obesity and Adipose Tissue Inflammation
Both obesity and the metabolic syndrome are associated with chronic low-grade
inflammation, which is intimately associated with the development of CVD. Adipose
tissue plays an important role in storing lipid in the form of TG, as well as secreting a
variety of adipokines and cytokines that control many of the physiological processes in
the body (119). However, during obesity, in order to compensate for the excess TG load,
adipose tissue undergoes rapid expansion, resulting in adipocyte hypertrophy (119).
Several mouse models have demonstrated obesity-related increases in macrophage
infiltration into adipose tissue, leading to inflammatory cytokine production (120,121).
High-fat fed agouti yellow and LDLR knockout mice (Ldlr^) mice had significantly
elevated TNFa, IL-6, MCP-1 and macrophage inflammatory protein-1 a (MIP-1a)
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expression in white adipose tissue (WAT), which correlated with increased body weight
( 122).

It has been suggested that adipose tissue inflammation may contribute to insulin
resistance. In ob/ob mice, macrophage infiltration into adipose tissue preceded the
development of hyperinsulinemia (120). Furthermore, mice lacking TNFa expression in
adipose tissue macrophages have reduced adipose tissue accumulation and enhanced
insulin sensitivity (123), thereby implicating the local inflammation in adipose tissue with
insulin resistance.
There are several factors that may initiate macrophage recruitment. Increased
FA flux to adipose during obesity, thereby activating the classical inflammatory signaling
receptor, toll-like receptor 4 (TLR4), is thought to play a role in mediating adipose tissue
inflammation (124,125). The hormone leptin, which is in overabundance of during
obesity, has been shown to be a chemoattractant for monocytes and macrophages in
vitro (126). In mice, over expression of MCP-1 in adipose tissue resulted in increased
macrophage infiltration and enhanced inflammatory cytokine expression (127). Hypoxia,
which often results in obese adipose tissue due to rapid expansion, has been shown to
elevate the expression of inflammatory cytokines (128,129). As a result of hypoxia,
adipocyte death often occurs in obesity, and therefore macrophages may be recruited in
order to phagocytose dead adipocytes (130). It is likely a combination of all of these
factors that provides a stimulus for macrophage infiltration into adipose tissue.
1.6.1 Adipose Tissue Inflammation and Dietary Cholesterol
Recently, it has been demonstrated that the addition of cholesterol to a high-fat
diet in Ldlrv' mice significantly increased macrophage infiltration into white adipose
tissue, contributing to systemic inflammation and increasing atherosclerosis, compared
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to mice fed a high-fat diet alone. Although the exact mechanism through which
cholesterol

exacerbated adipose tissue inflammation

is unknown, the authors

hypothesized that increased delivery of cholesterol and oxysterols to adipose tissue from
chylomicron particles may be cytotoxic to adipocytes, thereby promoting macrophage
infiltration (131,132).
1.6.2 Obesity, Systemic Inflammation and Atherosclerosis
There is an abundance of evidence to suggest that obesity is associated with
increased systemic inflammation, and may therefore increase the risk for cardiovascular
events (133). Studies have shown a direct correlation between increased body mass
index (BMI) and increased levels of the inflammatory proteins C-reactive protein (CRP),
interleukin 6 (IL-6) and serum amyloid A (SAA) in the circulation (134). Conversely,
weight loss has been shown to reduce the circulating levels of these inflammatory
markers (134). Elevated CRP levels in humans are associated with an increase in
cardiovascular risk factors including metabolic syndrome, insulin resistance and
dyslipidemia (135,136). Cholesterol feeding in LdlrA mice has been shown to increase
circulating serum SAA, which enhanced the development of atherosclerosis due to the
ability of SAA, an apolipoprotein found in HDL, to bind to vascular proteoglycans,
promoting the adhesion of lipoproteins to the vessel wall (137). Furthermore, cholesterol
feeding in lean, insulin sensitive humans has also been shown to increase circulating
CRP and SAA levels (138). Therefore, treatments that can effectively attenuate systemic
inflammation, particularly the inflammation associated with obesity and adipose tissue
expansion, may be important for preventing cardiovascular disease.
1.7 Atherosclerosis
1.7.1 Progression

30

Atherosclerosis can be viewed as a chronic-inflammatory disease developing
over many years and even decades (139) (Figure 1-3). It has been established that
elevated plasma LDL levels are an independent factor for the development of
atherosclerosis (140,141). The initiation of atherosclerosis occurs when apoBIOOcontaining lipoproteins, including LDL and VLDL, permeate the artery wall and
accumulate in the subendothelial space (141). The retained lipoprotein particles are
prone to oxidative modification by myeloperoxidases, lipoxygenases and reactive
oxygen species, and are therefore referred to as oxidized LDL (oxLDL) species (141).
The accumulation of oxLDL particles activates the overlying endothelium, increasing the
expression of adhesion molecules including E-selectin and vascular cell adhesion
molecule 1 (VCAM-1). Various chemokines are also secreted, that attract circulating
monocytes, dendritic cells and T-cells into the lesion (142). Under the influence of the
macrophage

colony-stimulating

factor

(M-CSF),

monocytes

differentiate

into

macrophages (143).
Oxidative modification of LDL particles facilitates their uptake by macrophages
via CD36, resulting in increased lipid accumulation and the formation of macrophage
“foam cells”, named for their foamy appearance (144). Dendritic cells are also present in
atherosclerotic lesions and recent research suggests that they may play an important
role in the initiation of atherosclerosis, as they can also accumulate lipid (145).
Macrophage foam cells are instrumental in contributing to the inflammatory response
associated with lesion formation, as they secrete a variety of pro-inflammatory mediators
including cytokines and chemokines (146). At this time, the lesion is classified as a type
II lesion or a “fatty streak”, characterized by the layering of macrophage foam cells and
the accumulation of lipid-laden smooth muscle cells (SMC) (147).
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Figure 1-3. Atherosclerotic Lesion Characterization and Progression
Atherosclerosis is a characterized as a chronic inflammatory disease
developing over decades. The accumulation of apoB100-rich particles
contributes to endothelial dysfunction, resulting in lipid accumulation in the
intima, called a “fatty streak”. Macrophage foam cells take up lipid and secrete
a variety of pro-inflammatory cytokines that potentiate lesion formation. SMCs
migrate from the medial layer of the artery and deposit extracellular matrix
proteins and collagen in attempt to stabilize the lesion. Complicated lesions
contribute to morbidity and mortality due to plaque rupture and thrombosis.
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Type III lesions or intermediate lesions, develop when extracellular lipid droplets
accumulate and disrupt the intimal SMCs (147). Foam cells further promote lipoprotein
retention by secreting extracellular matrix molecules, and the increased inflammatory
cytokine production results in recruitment of more T cells, mast cells and neutrophils (2).
Type IV lesions arise with the development of the lipid core, a dense accumulation of
extracellular lipid that thickens the artery wall, but fails to narrow the vascular lumen
(148). As the lesion progresses, new fibrous connective tissue, mainly collagen, is
secreted by myofibroblasts and SMCs, which surrounds and stabilizes the lipid-rich core
and is known as the “fibrous cap”. These lesions are classified as type V, and often
result in narrowing of the lumen (148).
In advanced lesions, macrophages can undergo apoptosis due to persistent ER
stress. However the efferocytosis, or clearance, of apoptotic cells is inefficient, therefore
contributing to an accumulation of dead cells in the lesion core (149). Eventually, SMC
apoptosis and degradation of the extracellular matrix results in weakening of the fibrous
cap, increasing the susceptibility for plaque rupture (149). Platelets can adhere to the
plaque, particularly following rupture, promoting thrombus formation. If the thrombus is
large enough, it can occlude the artery and lead to nutrient and oxygen deprivation,
potentially resulting in myocardial infarction (150). Lesions of this severity are classified
as Type VI and account for the morbidity and mortality associated with atherosclerosis
(148).
1.7.2 Inflammation and Atherosclerosis
As mentioned above, atherosclerosis is an inflammatory disorder whereby cells
of the atherosclerotic plaque secrete and are activated by low-molecular-weight protein
molecules called cytokines (151). There are two different kinds of cytokines that
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participate in atherosclerosis; Th1-related cytokines, which are considered to be
proinflammatory, and Th2-related cytokines, which have anti-atherogenic properties
(151). A diverse range of cytokines are expressed in human atherosclerotic lesions,
including TNFa, several members of the interleukin family such as IL-1, IL-2 and IL-18,
and M-CSF (151). Many studies have revealed the importance of these cytokines in
potentiating atherogenesis. Mice lacking both TNFa and apoE have decreased
atherosclerotic lesion area in the aortic sinus compared to mice lacking apoE only (152).
Similarly, an IL-1 receptor antagonist prevented the formation of fatty streak lesions in
apoE7' mice (153). Treatment of high-fat fed apoE deficient mice with recombinant IL-6
protein increased circulating levels of proinflammatory cytokines and enhanced lesion
area approximately 2-fold (154).
In addition to cytokines, another class of small molecular-weight proteins called
chemokines are involved in attracting and activating leukocytes during atherosclerosis.
Chemokines, and their associated chemokine receptors, are involved in many
physiological processes in the body including immunity, development, and wound repair
(155). However, studies have revealed that chemokines play an important role, not only
in the recruitment of inflammatory cells to atherosclerotic lesions, but also in the
recruitment of macrophages into adipose tissue during obesity (155). Knockout of MCP1 in mice expressing human apoB100 dramatically reduces macrophage infiltration into
atherosclerotic lesions, thereby preventing plaque formation (156). Diet-induced
atherosclerosis was also reduced in mice lacking both apoE and CC-chemokine receptor
5, the endogenous receptor for MIP-1a, resulting in a more stable plaque phenotype
(157). Therefore, atherosclerosis is a state of continual chronic inflammation and
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understanding the inflammatory processes that mediate lesion development are of
significant therapeutic interest for the prevention and treatment of atherosclerosis.
1.8 Flavonoids
1.8.1 Flavonoids and Disease
Flavonoids are polyphenolic molecules that are present in our daily diet, in plantderived foods such as fruits, vegetables, seeds, nuts, wine, and tea (158). There are
several classes of flavonoids, which group the molecules based on their carbon structure
and level of oxidation. These include flavanones, flavonols, flavones, flavan-3-ols,
anthocyanins and isoflavones (Table 1-2). Polyphenolic molecules are known for their
potent antioxidant properties, however their structure, and therefore class, defines their
bioavailability and activity in the body (158). Several reports have demonstrated a
relationship between the consumption of flavonoid-rich diets and the prevention of
diseases including cancer (159), stroke (160) and osteoporosis (161). Epidemiological
evidence suggests a significant inverse relationship between flavonoid intake and
cardiovascular disease mortality (162,163). However, these findings are based on
flavonoid intake from food sources, and are therefore affected by the abundance in the
food as well as the bioavailability. Furthermore, inter-individual bioavailability often
defines the effectiveness of flavonoid molecules in studies of human disease. Therefore,
the use of purified flavonoid molecules is the most useful assessment of their
effectiveness.
1.8.2 Flavonoids and Cardiovascular Disease
Flavonoids have been shown to have beneficial effects on many aspects of
cardiovascular disease including endothelial function, lipoprotein metabolism and
atherogenesis(164). A mixture of polymethoxylated flavonoids administered to fructose-
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Table 1-2 Flavonoid Classification
Major Flavonoid
Classes

Structure

Family members

Dietary
Sources

Naringenin , Hesperitln,
Eriodictyol

Citrus fruits,
Tomatoes

Quercetin,

Onions, Apples, Broccoli,
Cranberries

Myricetin,

Berries, Grapes, Parsley,
Spinach

Isorhamnetin, Kaempferol,
Pachypidol, Rhamnazin,

Apigenin
Nobiletin, Tangeritin
Lueolin

Celery, Lettuce,
Parsley
Citrus Fruits
Beets, Bell peppers,
Spinach,
Brussel Sprouts,
Thyme

Catechins
Epigallocatechin gallate

Tea, Red wine, Cocoa,
Grapes, Plums
Tea, fruits,
legumes

Epicatechins, Epicatechin
gallate
Cyanidin, Delphinidin, Peonidin, Red Wine,
Malvidin, Pelargonidin
Blueberries
Cranberries, Black
currants
Plums, Red onions, Red
potatoes
Isoflavones
(Isoflavonoids)

Daidzein, Genistein, Glycitein

Soy Products
Red Clover

Polyphenol
Compounds
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fed insulin-resistant hamsters improved glucose homeostasis, reduced plasma TG and
cholesterol, and suppressed the expression of adipokines from adipose tissue (165).
Resveratrol, a polyphenolic molecule found in red wine that resembles the
flavonoid structure, improved endothelial function in mice with type 2 diabetes, by
preventing TNFa-induced oxidative stress (166).

Long-term supplementation of

resveratrol to apoE deficient mice prevented cholesterol synthesis, leading to a reduction
in atherosclerotic lesion formation (167).
Recently, the ability of the polymethoxylated flavone nobiletin, mainly found in
tangerines, to improve many of the aspects of the metabolic syndrome has been
established in a mouse model of diet-induced insulin resistance. Supplementation of
nobiletin to a high-fat diet in Ldlr/~mice reduced VLDL-TG secretion from the liver and
prevented hepatic steatosis. Nobiletin also prevented hepatic glucose production and
enhanced insulin sensitivity via increased peripheral glucose disposal. Collectively,
these metabolic improvements led to an 83% reduction in atherosclerotic lesion area in
the aortic root (168).
This thesis focuses on a citrus flavanone, found mainly in grapefruit, called
naringenin. Several earlier studies from our group have elucidated the role of naringenin
in modulating insulin signaling, glucose homeostasis and lipid metabolism. In vitro
studies using human HepG2 hepatocytes have shown that naringenin can prevent both
ACAT1/2 and MTP activity, resulting in reduced lipid availability for apoB100 secretion
(169). Naringenin also increases the proteasomal degradation of apoB100 from oleatestimulated HepG2 cells (170). Similar to insulin, naringenin can prevent apoB100
production through activation of the PI3-K (171) and MAPKerk pathways (103). Moreover,
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the activation of PI3-K and MAPKerk by naringenin was independent of activation of the
insulin receptor and or IRS-1 (172).
Recently, it has been demonstrated that the addition of naringenin to a high-fat,
western diet in Ldlrr/' mice prevented diet-induced obesity, hyperinsulinemia and
dyslipidemia (173). Naringenin reduced Srebp7-c-mediated lipogenesis, prevented
hepatic TG and cholesterol synthesis, increased hepatic FA oxidation and improved
overall insulin sensitivity and glucose tolerance (173). The reduced lipid accumulation in
the liver was associated with a reduction in hepatic VLDL production (173), and a
subsequent prevention of atherosclerotic lesion development (174). Therefore, these
studies highlight the role of the citrus-derived flavonoid naringenin in preventing
metabolic dysregulation associated with high-fat feeding in mice.
1.9 In vivo Models Used
1.9.1 Mouse Models
1.9.1.1 C57BL76 Mice
The C57BL/6 mice are the most susceptible inbred strain to the development of
diet-induced atherosclerosis (175). When fed the Paigen diet, which is high in
cholesterol (1.25% wt/wt), fat (15% wt/wt) and sodium cholate (0.5% wt/wt), for
prolonged periods, mice develop lesions in the aortic root that consist of lipid-laden
macrophage foam cells, with some evidence of cellular debris and collagen (176).
However, these lesions do not closely resemble human atherosclerotic lesions (176),
and therefore, gene-targeted mouse models have been developed. The C57BL/6 strain
was used in Chapter 3, and both the Ldlr'' (Chapter 2) and FGF21 knockout (Fgf21'')
(Chapter 3) strains were backcrossed ten times with the C57BL/6 strain.
1.9.1.2 Ldlr'' Mice
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LdlrrA mice are a useful in vivo model of atherosclerosis, as these mice are
susceptible to diet-induced hypercholesterolemia (177) and atherosclerosis (178). When
fed the Paigen diet, Ldlr'' mice will develop large atherosclerotic lesions in the aortic root
and throughout the aorta that resemble atherosclerotic lesions found in humans (178).
Unlike wildtype C57BL/6 mice, where most of the plasma cholesterol is carried in the
HDL fraction, Ldlr'' mice have a similar plasma lipoprotein profile to humans, in which
cholesterol is mainly carried in the LDL fraction (177). Upon feeding the Paigen diet,
there is a significant increase in cholesterol in the VLDL, IDL and LDL fractions (178).
Placing Ldlr'' mice on a high-fat, western diet consisting of 42% calories from fat with
low levels of cholesterol (0.02%) for 4 weeks, induces a state of obesity and insulin
resistance, with elevated blood glucose and plasma insulin levels (179). Therefore, Ldlr'
mice are a useful model for the study of dyslipidemia, and insulin resistance associated
with high-fat, high-cholesterol diets. These mice were used in the studies performed in
Chapter 2.
1.9 . 1.3 Fgf2l 'm c e

F g f2 l' mice were generated by Badman et at. (78) and were viable and fertile.
The generation of Fgf2T' mice revealed that, when fed a ketogenic diet (high-fat, lowcarbohydrate), a diet that models the fasted state, Fgf2V' mice develop hepatic
steatosis, and have impaired ketogenesis and glucose control. However, the impact of
feeding Fgf21v' mice a high-fat, western diet has not been established, and the studies in
this thesis will determine the importance of FGF21 in a model of diet-induced obesity
and insulin resistance. The Fgf2V' mice used in Chapter 3 were obtained from Dr. Chris
Pin (Physiology and Pharmacology Department, UWO) who received the mice from his

39

collaborator Alexei Kharitonenkov at Lily Research Laboratories in Indianapolis Indiana
(78).
1.9.2 Mouse Diets
1.9.2.1 Chow Diet
A standard laboratory chow diet (Harlan Teklad, TD 8604) was used as a basis
of comparison for the metabolic indices induced by the high-fat, high-cholesterol (HFHC)
diet and often serves as the control diet in mouse metabolic studies (179). The diet is a
fixed formula diet that supports the normal gestation, lactation and growth of mice (Table
1-3). Small amounts of flavonoids, including isoflavones (genistin and daidzin) may be
present in the diet due to the presence of soybean oil and other plant-based
components. The chow diet contains 14% of calories from fat and has a caloric density
of 3.0 kcal/g. This diet was used in both Chapters 2 and 3.
1.9.2.2 Western Diet
The western diet (Harlan Teklad, TD96125) has been established to induce
metabolic indices in Lcf/r7' mice including obesity, insulin resistance, dyslipidemia and
atherosclerosis (179). The western diet consists of 42% of calories from fat, 43% of
calories from carbohydrate and 15% of calories from protein (Table 1-3). The main
sources of fat includes anhydrous milk fat and lard, and the FA profile consists of 58%
saturated,

36%

monounsaturated

and

5%

polyunsaturated.

The

carbohydrate

component of the diet consists largely of sucrose (30% of calories), whereas the protein
is derived from casein. This diet differs from the Paigen diet mentioned above, because
it has relatively low levels of cholate, less fat and a modest amount of cholesterol
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Table 1-3 Mouse Diets

Formula

Chow Diet

Western Diet

High-Fat,
High
Cholesterol
(HFHC) Diet

TD 8604

TD 96125

TD 09268

g/kg
Casein
Dl-Methionine
Sucrose

‘ See represented
ingredients, exact
amounts not
specified

Corn starch

Low-Fat, High
Cholesterol
(LFHC) Diet

TD AIN-76A

TD 09801

g/kg

g/kg

195

195

200

200

3

3

3

3

341.46

341.46

497.99

497.99

150.75

150.75

150

150

50

50

Corn Oil
160

Anhydrous Milkfat

Low-Fat
(LF) Diet

160

Lard, (Pork)

50

50

Cellulose

36.73

35.13

50

50

Mineral Mix

50

50

35

35

Zinc Carbonate

0.04

0.04

Vitamin Mix

10

10

10

10

Choline Bitartrate

3

3

2

2

Ethoxyquin

0.02

0.02

0.01

0.01

Macronutrients
% by weight
(% calories)
Protein

24.3 (32)

17.3(15.2)

17.3 (15.2)

17.7(18.8)

17.7(18.8)

Carbohydrate

40.2 (54)

48.7 (42.8)

48.7 (42.8)

64.9 (68.8)

64.7 (68.8)

Fat

4.7 (14)

21.2(42.0)

21.2(42.0)

5.2 (12.4)

5.2 (12.4)

kcal/g

3.0

4.5

4.5

3.8

3.8

Cholesterol

0.005%

0.05%

0.2%

0.0%

0.2%

‘ Represented Ingredients: Dehulled soybean meal, wheat middlings, flaked corn, ground corn, fish
meal, soybean oil, brewers dried yeast,cane molasses, dried whey, dicalcium phosphate, calcium
carbonate, iodized salt, choline, chloride, magnesium oxide, Vitamin A acetate, Vitamin D3 Vitamin
E, niacin, pyridoxine hydrochloride, menadione, sodium,bisulfite, Vitamin B 12, manganous oxide,
ferrous .sulfate copper sulfate, zinc oxide, calcium, iodate,cobalt carbonate, chrominum, potassium
sulfate, kaolin
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(0.05%). The caloric density of the western diet is 4.5 kcal/g. This diet was used for
studies in Chapter 3.
1.9.2.3 High-Fat, High-Cholesterol (HFHC) Diet
The HFHC diet (Harlan Teklad, TD 09268) is a modification of the TD96125
western diet, with the only difference being the addition of 0.15% cholesterol, such that
the total cholesterol content is increased 4-fold from 0.05% to 0.2% (Table 1-3).
Although 0.2% cholesterol is moderate relative to the Paigen diet, which contains 1.25%
cholesterol, (176) we have called this a HFHC diet. The caloric density of the HFHC diet
is 4.5 kcal/g. Diets with the same or similar amounts of cholesterol have been shown to
induce

hypercholesterolemia,

hepatic

and

adipose

tissue

inflammation,

and

atherosclerosis (94,131,132,180). The HFHC diet was used in Chapter 2.
1.9.2.4 Low-Fat (LF), Semi-Synthetic Diet
The low-fat (LF) diet (Harland Teklad, AIN-76A), is a semi-synthetic diet
consisting of 12.4% calories from fat, mainly from corn oil (Table 1-3). This diet is
comprised of 68.8% calories from carbohydrate, which are derived mainly from sucrose
(77%). Unlike the chow diet, the LF diet does not contain any soy isoflavones. The LF
diet contains virtually no cholesterol or cholate and has a caloric density of 3.8 kcal/g.
This diet was used as the control for the low-fat, high cholesterol (LFHC) diet used in
Chapter 2.
1.9.2.5 Low-Fat, High-Cholesterol (LFHC) Diet
The LFHC diet (Harlan Teklad, TD09801) is a modification of the LF diet (AIN76A), with the only difference being the addition of 0.2% cholesterol (Table 1-3). The
addition of 0.15% cholesterol to the LF diet has been used in Ldlr'A mice, as a model of
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atherosclerosis (181). Although 0.2% cholesterol is moderate relative to the Paigen diet,
which contains 1.25% cholesterol, (176) we have called this a LFHC diet. The LFHC diet
has a caloric density of 3.8 kcal/g and was used in Chapter 2.
1.10 Hypothesis and Scope of Thesis
Over the past two decades, the incidence of the metabolic syndrome has been
on the rise, as the number of people diagnosed with obesity, insulin resistance and
cardiovascular disease is now a global pandemic (182). Dyslipidemia, including the
elevated plasma LDL- and VLDL-cholesterol associated with hypercholesterolemia, is a
significant risk factor for the development of atherosclerosis (32). Furthermore, diets rich
in cholesterol have been shown potentiate the chronic low-grade inflammation
associated with obesity and cardiovascular disease (131,132). Therefore, identifying
novel methods of prevention and treatment of these metabolic diseases is of importance.
The studies in this thesis employ an in vivo model of obesity, insulin resistance
and atherosclerosis to explore the preventative and therapeutic properties of the citrus
flavonoid naringenin. Using Ldlr^ mice, the ability of naringenin to attenuate hepatic
lipoprotein overproduction, hepatic steatosis, and insulin resistance associated with
cholesterol-feeding was examined. Furthermore, the effect of naringenin on preventing
cholesterol-induced increases in local inflammation in the liver and adipose tissue, and
the impact on the inflammation associated with atherogenesis was determined. The use
Fgf21'/~mice, a unique model of metabolic dysregulation, established the importance of
FGF21 in mediating the physiological response to a high-fat diet. Finally, the ability of
naringenin to mediate its preventative effects, independent of FGF21, provided insight
into naringenin’s mechanism of action. Therefore, Chapters 2 and 3 of this thesis
address the following hypotheses:
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1. The citrus flavonoid naringenin can prevent cholesterol-induced dyslipidemia,
insulin insensitivity, inflammation and atherosclerosis in Ldlrv' mice. (Chapter
2)

2. The administration of a high-fat diet to Fgf2T/' mice, potentiates metabolic
dysrégulation, including obesity, and hepatic steatosis, compared to wild-type
mice. (Chapter 3)
3. The addition of naringenin to a high-fat diet restores normal metabolic
function in Fgf21'/ mice (Chapter 3).
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CHAPTER 2
Naringenin prevents cholesterol-induced dyslipidemia, insulin insensitivity,
inflammation and atherosclerosis in Ldlr/' mice.
2.1 Introduction
Metabolic

syndrome

is a collection

of abnormalities

including

obesity,

dyslipidemia, hypertension, and insulin resistance, all of which contribute to the
development of type 2 diabetes and atherosclerosis. Insulin resistance, a central
component of the metabolic syndrome, is contributed to by enhanced free fatty acid
(FFA) flux from expanded visceral adipose tissue associated with obesity (1). The
overabundance of plasma FFA results in ectopic lipid accumulation in peripheral tissues,
such as muscle and liver, which impairs insulin signaling and contributes to whole-body
insulin resistance (2). In the liver, reduced insulin sensitivity results in increased
gluconeogenesis and lipogenesis (2,3), leading to the over-secretion of apolipoprotein
B100 (apoBIOO)-containing lipoproteins including very low-density lipoprotein (VLDL)
and low-density lipoprotein (LDL), contributing to dyslipidemia (4). Both insulin
resistance and dyslipidemia are risk factors for the development of cardiovascular
disease (4).
Potentiating insulin resistance and atherosclerosis is the development of a
chronic-low grade inflammatory response. In insulin resistant states, monocyte-derived
macrophages can infiltrate visceral adipose tissue, resulting in the synthesis of pro
inflammatory cytokines. Cytokine production can originate from adipocytes or resident
macrophages, and synergistically activate a local inflammatory response that can impair
insulin sensitivity (5-7). Recently, Subramanian et al. demonstrated that feeding Ldlr/'
mice a diabetogenic (high-fat) diet rich in cholesterol, markedly increased macrophage
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accumulation in adipose tissue compared to mice fed a diabetogenic diet with no added
cholesterol (8). Interestingly, the addition of cholesterol increased systemic inflammation,
enhanced plasma insulin concentrations, and worsened atherosclerosis, compared to
mice fed the diabetogenic diet alone (9). Therefore, the pro-inflammatory state
associated with adipose tissue expansion in mice can be exacerbated by cholesterol
feeding, which may enhance insulin resistance and atherosclerosis (8).
High dietary cholesterol has also been shown to impact inflammation in the liver.
In Ld/r7' mice it has been demonstrated that the addition of cholesterol to a high-fat diet
is sufficient to promote hepatic inflammation, as indicated by increased expression of
inflammatory cytokines and macrophage markers (10,11). Other work has established a
link between hepatic inflammation and dyslipidemia, as the inflammatory proteins tumor
necrosis factor a (TNFa) and interleukin-1 (3 (IL-1p) can stimulate the overproduction of
apoBIOO-containing lipoprotein particles from the liver (12,13). These data suggest that
increased dietary cholesterol promotes hepatic inflammation, potentially contributing to
dyslipidemia.
Together,

cholesterol-induced

metabolic

disturbances

and

inflammatory

responses significantly contribute to the development of atherosclerosis. In particular,
increased levels of small, dense, cholesterol-rich LDL particles in the plasma are a risk
factor for atherosclerosis, due to their ability to permeate the artery wall upon endothelial
damage. These particles are susceptible to oxidation and are taken up in an unregulated
manner by macrophages in the artery wall, contributing to foam cell formation (14,15).
The systemic inflammatory response associated with the metabolic syndrome may also
contribute to atherogenesis. In particular, the increase in SAA, an inflammatory mediator
secreted from the liver has direct effects on potentiating inflammation at the artery wall,
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both in vitro and in vivo (16). Therefore, it is imperative that effective pharmacological
therapies for the treatment and prevention of the chronic low-grade inflammation
associated with atherosclerosis are discovered.
Epidemiological studies have shown that the consumption of naturally occurring
compounds called flavonoids is associated with a reduced risk of developing
cardiovascular disease. (17). Flavonoids have also been demonstrated to have anti
inflammatory properties (18-20). Naringenin, a citrus flavonoid found in grapefruit,
inhibits diet-induced obesity, prevents hepatic TG accumulation through an increase in
hepatic fatty acid (FA)-oxidation, and reduces the progression of atherosclerosis in Laf/r7'
mice fed a high-fat diet (21,22). However, these studies were performed in the context of
diets that contain relatively low levels of cholesterol (0.05%). Due to the evidence that
diets with higher amounts of cholesterol may intensify the inflammatory response
associated with obesity and atherosclerosis (8,9), one objective of the present studies
was to examine the potential of naringenin to prevent metabolic dysregulation, and
attenuate both the inflammatory response and atherosclerosis, in mice fed a diet high in
fat and cholesterol.
In previous studies, the primary protective mechanism for naringenin was
stimulation of hepatic FA-oxidation, together with decreased hepatic FA-synthesis,
leading to a marked reduction in plasma lipid concentrations, prevention of ectopic lipid
deposition and attenuation of atherosclerosis (21,22). This raised the possibility that
naringenin would only provide the metabolic protection required for the attenuation of
atherosclerosis in the context of a high-fat diet. Diets low in fat, but high in sucrose and
containing moderate amounts of cholesterol have been reported to induce significant
atherosclerosis in Ldlr/' mice (23). Therefore, a second objective of the current study
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was to examine the ability of naringenin to improve metabolic parameters, prevent the
inflammatory response, and attenuate atherosclerosis in mice fed a low-fat, cholesterolcontaining diet.
Studies were conducted in Ldlrv' mice fed a high-fat (42% kcal), high-cholesterol
(0.2%) (HFHC) diet or a low-fat (14% kcal), high-cholesterol (0.2%) (LFHC) diet. In these
two in vivo mouse models of atherosclerosis, we report that naringenin supplementation
to either the high-fat or low-fat, cholesterol-rich diet, prevents obesity and adipose tissue
accumulation, and attenuates dyslipidemia and hyperinsulinemia. By modulating the
expression of genes that regulate hepatic FA-oxidation and lipogenesis, naringenin
prevented the development of hepatic steatosis. The cholesterol-induced inflammation in
both the liver, and adipose tissue, were also completely alleviated by naringenin
treatment. Collectively, the reduction in plasma lipids, improved insulin sensitivity, and
decreased

local

inflammation

was

associated

with

a

marked

attenuation

of

atherosclerosis.

2.2 Research Design and Methods
2.2.1 Animals and Diets
Male Ldir^ mice on a C57BI/6J background (Jackson Laboratory, Bar Harbour,
ME, USA), 8-12 weeks of age, were housed in pairs, on a 12-hour light/dark cycle, at
23°C and handled in accordance with the Animal Care and Use Subcommittee at the
University of Western Ontario. In the first study, mice were fed ad libitum for twelve
weeks (n= 12/group) either a standard chow diet (14% kcal fat, TD8604, Harlan Teklad,
Madison, Wl), a high-fat, high-cholesterol diet (HFHC, 42% kcal fat, 0.2% cholesterol,
TD09268, Harland Teklad), or the HFHC diet supplemented with 3% wt/wt naringenin
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(Sigma-Aldrich, St. Louis, MO). In the second study, mice were fed ad libitum for twelve
weeks (n= 12/group) either a low-fat, semi-synthetic diet (LF, 12.4% kcal fat, 52% kcal
sucrose, AIN-76A, Harlan Teklad), a low-fat, high-cholesterol diet (LFHC, 12.4% kcal fat,
52% kcal sucrose, 0.2% cholesterol, TD.09801, Harlan Teklad) or the LFHC diet
supplemented with 3% wt/wt naringenin. Food intake and body weight measurements
were conducted three times per week. Caloric intake was calculated as weight of food
eaten (g) multiplied by the caloric content of each diet (Chow; 3.1 kcal/g, HFHC; 4.5
kcal/g, LF and LFHC; 3.8 kcal/g). Mice were fasted for 6 hours before sacrifice.
2.2.2 Blood and Tissue Collection
At sacrifice, animals were anesthetized with Avertin (0.015-0.017 ml/g body
weight) and blood was collected via cardiac puncture in syringes containing 80 pi of 7%
Na2-EDTA. Blood was centrifuged at 14,000 rpm for 5 minutes at 4°C to separate the
plasma, which was stored at -20°C for further use. To dissect the heart for histological
analysis, the left ventricle was perfused with heparin-phosphate buffered saline (PBS)
(10 units/ml) and the right atrium was cut to drain the perfusate. The heart and full-length
aorta were dissected together. The heart was removed, placed in Optimum Cutting
Temperature medium (OCT) and frozen on dry ice. The aorta was placed in 10%
formalin. All other tissues including the liver and adipose tissue, were removed, weighed,
snap frozen in liquid nitrogen and stored at -80°C.
2.2.3 Plasma Analysis
Plasma concentrations of insulin, leptin (Alpco Diagnostics, Windham, NH, USA)
and SAA (Invitrogen Life Technologies; Mississauga, ON, Canada) were determined in
plasma samples by mouse-specific ELISA as per manufacturer’s instructions. Plasma
concentrations of triglyceride and total cholesterol (Roche Diagnostics, Laval, QC,
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Canada) were measured enzymatically on a Cobas Mira S autoanalyzer. The total
cholesterol (TC) and triglyceride (TG) within VLDL, LDL and HDL particles were
determined in fresh EDTA-plasma by Fast Performance Liquid Chromatography (FPLC),
using an AKTA purifier and a Superose 6 column. A constant flow rate of 0.4 ml/min was
used to collect 500 pi fractions. A 50 pi aliquot was used to measure cholesterol and
triglyceride enzymatically in both samples and standards (Roche Diagnostics) on a
microtitre plate with 150 pi reagent (TG, Roche Diagnostics; Cholesterol; Wako,
Richmond, VA, USA).
2.2.4 Tissue Lipids
Hepatic and aortic lipids were extracted from 100 mg pieces of liver and 20 mg
pieces of aorta, obtained at sacrifice using the Folch et al. method (24). Quantitation of
hepatic and aortic lipids were determined as described previously (25). Briefly, for
quantitation of TG, free cholesterol (FC), and TC in the liver, [3H] cholesteryl oleate
(Amersham Canada Ltd, Oakville, ON, Canada) was added to assess recovery. TG, FC,
and TC were quantitated in liver lipid extracts. In brief, both a 200 pg/mL cholesterol
standard and 200 pg/mL triolein standard were prepared in isopropanol, and 0, 2-, 4-, 8-,
16-, 32-, and 64-pg (64-pg for TG only) standard solutions were made. Samples and
standards were dried under N2 and 500 pL of a 1% Triton X-100 solution in chloroform
was added. Once samples were solubilized and dried under N2, deionized water (50 pi)
was added and TG, TC, and FC were determined by enzymatic, colorimetric assays (TG,
Roche Diagnostics; TC and FC; Wako) as per manufacturer’s instructions. Cholesteryl
ester (CE) was determined as the difference between TC and FC.
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2.2.5 Glucose and Insulin Tolerance Tests
Glucose tolerance tests (GTT) were conducted in mice fasted for 6 hours and
injected intraperitoneally (i.p) with a 15% D-glucose solution in 0.9% NaCI at a dose of 1
g/kg body weight. Blood was collected from the saphenous vein and blood glucose was
measured using a hand-held glucometer (Acenscia Elite, Bayer Healthcare, Toronto,
ON, Canada) at 0, 15, 30, 45, 60, 90, and 120 minutes post-injection. For insulin
tolerance tests, after a 5-hour fast, mice were injected i.p. with 0.6 lU/kg Novolin ge
Toronto (Novo Nordisk, Mississauga, ON, Canada). Blood was collected from the
saphenous vein and blood glucose was measured as stated above every 15 minutes for
one hour.
2.2.6 TG and apoB100 Secretion
TG and apoB100 secretion into plasma was determined in mice fed either Chow,
HFHC, HFHC + 3% naringenin, LF, LFHC or LFHC+3% naringenin diet for 4 weeks, and
a minimum of 6 mice per group, per time point were used. The rate of TG secretion into
plasma was measured in mice fasted for 4 hours and injected i.p. with 1000 mg/kg
Tyloxapol USP (0.1g/ml in 0.9% saline) (Ruger Chemical Company, Linden, NJ, USA).
Following the injection of tyloxapol, mice were sacrificed by C 02 inhalation; blood was
collected at 0, 60 and 120 minutes by cardiac puncture and centrifuged at 14,000 rpm
for 5 minutes at 4°C to isolate plasma. For apoB100 secretion measurements, mice were
injected i.p. with 1000 mg/kg Tyloxapol and 200 pCi of Tran S35-label (1000 Ci/mmol, L[35S]-methionine and L-[35S]-cysteine, MP Biomedicals Inc., Irvine, CA, USA), and after
sacrifice by C 02 inhalation, plasma samples were obtained by cardiac puncture at 60
and 120 minutes (26). A combined VLDL/IDL fraction (density <1.019 g/ml) was isolated
from 250 pi of fresh plasma by ultracentrifugation at 120,000 rpm for 4 hours in Beckman
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Quickseal tubes (11x32 mm, Beckman Instruments Ltd, Mississauga, ON, Canada)
using a Beckman TLA 120.2 rotor in a Beckman Optima TLX ultracentrifuge (Beckman
Instruments). Proteins from VLDL/IDL fractions were separated on 4.5% SDS-PAGE
gels, which were subsequently placed in a fixing solution (30% methanol, 2.5% glacial
acetic acid 67.5% deionized water) for 30 minutes, dried and placed on a
phosphorimager screen for at least 5 days. Bands corresponding to apoB48 and
apoB100 were scanned using a Storm B20 Scanner (Amersham Biosciences,
Piscataway, NJ, USA) and quantitated using ImageQuant Software (Molecular
Dynamics, Sunnyvale, CA, USA) (27).
2.2.7 Cholesterol Absorption
Cholesterol absorption was determined in mice fed the experimental diets for 4
weeks as described previously (22). Mice were administered, by gavage, 150 pL of
medium chain triglyceride (MCT) oil (Novartis Medical Nutrition, Fremont, Ml, USA)
containing 1 pCi of [4-C14]-Cholesterol (Perkin Elmer, Waltham, MA, USA) and 2.0 pCi of
[5,6-H3]-(3-sitostanol (American Radiolabeled Chemicals Inc., St Louis. MO, USA). Mice
were housed individually in metabolic cages for 72 hours and feces were collected every
24 hours. To isolate cholesterol from the feces, samples were saponified in a 95%
EtOH/10N KOH solution. Neutral lipids were extracted by hexane. The ratio of [C14] to
[H3] was used to calculate the percentage of lipid absorbed. In all animals, the recovery
of radiolabeled sitostanol was 75-90%.
% Cholesterol Absorption =

[14C]/[3H] dosing mixture - [14C]/[3H] feces
[14C]/[3H] dosing mixture

X 100
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2.2.8 Tissue Sectioning and Histology
Immediately after dissection, a small piece of liver was placed in OCT medium
(Thermo Fisher Scientific, Waltham, MA, USA) and frozen at -80°C. Frozen liver
samples were sectioned at 8 pm using a Leica CM3050S cryostat (Leica Microsystems,
Concord ON, Canada). Liver sections were then stained with Oil Red O. Briefly, sections
were fixed with 40% formaldehyde for 30 minutes. A 0.5% stock solution of Oil Red O
dissolved in isopropanol was prepared, and a working solution (30ml of stock solution
and 20ml of PBS) was used to stain liver sections for 10 minutes, followed by a rinse in
deionized water and counter-stained using hematoxylin. Liver sections were also stained
with Hoechst 33258 (2.5 pg/ml, Sigma) in order to visualize the Oil Red O-stained lipid
droplets and nucleus (Hoechst) by fluorescence microscopy at 493 nm excitation.
White adipose tissue (WAT) was fixed in 10% formalin, embedded in paraffin,
sectioned using a Microm HM335E Microtome (Thermo Fisher Scientific, Nepean, ON,
Canada) and stained with hematoxlyin and eosin. Immunohistochemistry (IHC) was
conducted on WAT (paraffin embedded) and liver (frozen) for the macrophage marker
MAC-2. Briefly, slides were fixed in acetone, rinsed in PBS and quenched with
peroxidase blocking agent (3% H202 in methanol). Slides were blocked in 10% BSA and
incubated with rat anti-mouse MAC-2 antibody (1:1000) (Cedarline, Burlington, ON,
Canada) for 1 hour, followed by an incubation with a secondary antibody (biotinylated
goat anti-rat IgG antibody, (1:200) (Vector, Burlington, ON, Canada) for 30 minutes.
Sections were incubated in ABC reagent (ABC Elite Standard Kit, Vector) followed by a
short incubation in DAB substrate (DAB peroxidase substrate kit, Vector) and
counterstaining in hematoxylin. Slides were cover-slipped using Cytoseal xylene-based
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mounting medium (Thermo Fisher Scientific). Adipocyte diameter was calculated using
Northern Eclipse 7.0 software on 20x magnification photomicrographs.
At sacrifice, the top half of the heart was placed in OCT medium and frozen at 80°C. Frozen aortic sinus was prepared in cross-section by serial sectioning (90-100
sections per heart, 10pm) beginning at the aortic valves using a cryostat. In a similar
protocol as described above for MAC-2 staining, IHC was performed on sections of the
aortic

sinus

for

the

presence

of

macrophages

using

the

rat

anti-mouse

monocyte/macrophage antibody-2 (MOMA-2, Acurate; Westbury, NY, USA). In other
sections of the aortic sinus, a modified Verhoff and Masson’s Trichrome stain was used
to detect the presence of collagen (green) and elastin (black), and IHC was performed to
detect the presence of smooth muscle cells (SMC a-actin antibody, Clone 1AH, SigmaAldrich) at the Robarts Research Institute, Molecular Pathology Core Facility. The aortic
sinus was also stained with Oil Red O to detect the presence of lipid. These sections
were used for the quantitation of plaque area, in an average of 3-4 serial sections per
aortic sinus, using Axiovision 4.8 software (Carl Zeiss Canada Limited, Toronto, ON,
Canada). Morphometric analysis of atherosclerotic plaques was also performed on serial
sections. The relative area of atherosclerotic plaque that stained positive for MOMA-2,
collagen (trichrome) and SMC a-actin was determined relative to the total area of the
respective plaque using Axiovision 4.8 software. Lesion analysis began at the origin of
the aortic valves to ensure that a standard region was measured in each mouse.
Immediately following sacrifice, full-length aortas were dissected, fixed in 10%
formalin for 24 hours and carefully cleaned using a dissecting microscope to remove
excess adipose tissue. Aortas were stained with Sudan IV (Sigma-Aldrich). In brief, the
aorta was washed in distilled water, incubated in 70% ethanol and placed in Sudan IV
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for 15 minutes, followed by de-staining in 80% ethanol. A longitudinal slice from the
aortic arch to the abdominal aorta was made to expose the plaque on the intimal surface
(en face preparation). Aortas were mounted using glycerol gelatin (Sigma-Aldrich).
Stained lesion area was quantitated using Axiovision 4.8 software by dividing the stained
plaque area by the total area of the aortic arch (ascending and descending aorta),
expressed as a percentage. All photomicrographs were generated using an Olympus
BX50 microscope with a Qlmaging Retiga EXi FAST camera (Qlmaging, Surrey, BC,
Canada).
2.2.9 RNA Isolation and Quantitative Real-Time PCR
RNA was isolated from liver, adipose tissue, aorta and peritoneal macrophages
using the TRIzol reagent (Invitrogen) and mRNA concentrations were quantitated using
an

ND-1000

nanodrop

spectrophotometer

(Thermo

Fisher Scientific).

Reverse

transcribed total RNA at 10-50 ng/uL from each mouse were assayed in triplicate in 20
pL reactions using a two-step quantitative real time-PCR protocol. Gene-specific mRNA
quantitation was determined for all genes; (Ccl3 (Mip-1a), Ccl2 (Mcp-1), Saa1/2, Crp,
Tnfa, F4/80, 11-10, 11-6, Acat2, Acox, Srebp-2, Srebp-1c, Hmgcr, Pgc-1a, Cpt-1a, Fgf21,
Abcg5, Abcg8, Abcal, Abcgl and Cyp7a) on an ABI Prism (model 7900 FIT) Sequence
Detection System (Applied Biosystems, Streetsville, ON, Canada) according to the
manufacturer’s instructions. All primer probes sets were manufactured by Taqman®
Assays-on-Demand (Applied Biosystems) except Srebp-1c which designed from the
Mus musculus srebfl sequence (Genbank accession no. AL669954). The probe for
Srebplc overlapped the boundary between exon-1 specific for Srebplc and exon 2
(Applied Biosystems). Srebp- 1c forward primer: CAGGCCCGGGAAGTCACT, Reverse
primer: GACCACGGAGCCATGGATT, and probe: ATTTGAAGACATGCTCCA (Gene is

73

on the minus strand and primers have been designed as such). The standard curve
method was used to estimate specific mRNA concentrations. The expression of each
gene was normalized to Gapdh expression.
2.2.10 Mouse Peritoneal Macrophages (MPMs)
In a separate study, male Ldlr^' mice 8-12 weeks of age were housed in pairs, on
a 12-hour light/dark cycle, at 23°C and handled in accordance with the Animal Care and
Use Subcommittee at the University of Western Ontario. Animals were fed ad libitum (n=
16/group) either a standard chow, HFHC, or a HFHC diet supplemented with 3% (wt/wt)
naringenin. After 12 weeks, mice were injected i.p. with 2.5mL 4% Brewer’s
Thioglycollate Medium (Sigma-Aldrich), and 5 days later mice were sacrificed via C 02
inhalation. Each mouse was dissected down the midline to expose the intact peritoneal
cavity and 10 mis of cold PBS was injected, followed by light gentle massage of the
abdomen. The PBS mixture was carefully removed and centrifuged at 1500 rpm for 10
minutes at 4°C. Cells were resuspended in serum-free Dulbecco's modified Eagle's
medium (DMEM, Invitrogen) supplemented with geramycin (40 mg/ml, Merck-Frosst,
Kirkland, QC, Canada) and fungizone (20 pg/ml, Invitrogen). Cells were placed in 35mm
(6-well plates) at a density of 2.76-3.3x106 per well and were allowed to adhere for
approximately 2 hours, after which cells were washed 3 times with PBS.
2.2.11 Oil Red O Staining of MPMs
A subset of MPMs were plated into wells containing cover slips at the same
density as described above and allowed to adhere for 2 hours. Cells were washed with
PBS and stained with Oil Red O as described above for liver sections. After washing 3
times in PBS, the cover slip was removed from the well and mounted on a glass slide
using

Aquatex

aqueous

mounting

medium

(VWR,

Bridgeport

NJ,

USA).
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Photomicrographs were generated using an Olympus BX50 microscope with a Qlmaging
Retiga EXi FAST camera.
2.2.12 Cellular Lipid Mass
Cellular TC, CE and TG mass in MPMs were determined in cells extracted with
3:2 (vokvol) hexane:isopropanol (24). Cellular protein was extracted by 0.1 N NaOH and
was determined using a modified Lowry method (28). Standard solutions were made
from 200 pg/mL cholesterol and 200 pg/mL triolein in isopropanol at concentrations of 1,
2, 5, 10 and 20 pg. Samples and standards were dried under N2. For standards, 1ml of
chloroform and 1ml of 1% Triton X-100 was added. For samples 300 pL of CHCI3and
300 pL of 1% Triton were added. Samples and standards were dried under N2 and were
resolubilized in 500 pi (standards) and 150 pi (samples) of deionized water. TG, TC, and
FC were determined by enzymatic, colorimetric assays (TG, Roche Diagnostics; TC and
FC; Wako) as per manufacturer’s instructions. Cellular CE was determined by
subtracting FC from TC. Cellular lipids were normalized to cell protein.
2.2.13 Statistical Analysis
Data is presented as the mean ± SEM. Statistical analysis was performed using
a one-way ANOVA and post hoc Tukey test using Sigma Plot version 14.0. Data with
different letters are considered statistically different (P<0.05).

2.3 Results
Naringenin prevents diet-induced weight gain and adipose tissue expansion, in
cholesterol-fed mice.
To assess the effects of naringenin supplementation on diet-induced obesity in
cholesterol-fed Ldlrr/' mice, body weight and caloric intake were determined. In study 1,
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HFHC-fed mice gained significantly more weight throughout the 12 weeks on diet
compared to chow-fed controls. This rate of weight gain was prevented by
supplementation of the HFHC diet with 3% naringenin (Fig. 2-1 A). Caloric intake did not
differ between groups in study 1 (Fig. 2-1B). In the second study, the LF diet induced a
greater rate of weight-gain when compared to chow-fed control mice in study 1 (Fig. 21A), largely due to the significant amount of dietary sucrose, as high-fructose feeding in
mice has been shown to induce lipogenesis and weight gain (29). The addition of
cholesterol to the LF diet did not further impact body weight gain (Fig. 2-1 A). Conversely,
naringenin significantly prevented the high rate of weight gain observed in LFHC-fed
mice, despite a modest, yet significant increase in caloric intake (Fig. 2-1B).
The increased weight gain in HFHC-fed animals was attributed to a 4-fold
increase in the adiposity index, determined as epididymal fat pad weight normalized to
total body weight (Fig. 2-1C). Adiposity index was completely normalized by the addition
of naringenin (Fig. 2-1C). Although no significant difference in adiposity index was
observed between LF and LFHC-fed animals, naringenin markedly prevented adipose
tissue accumulation to levels resembling chow-fed mice (Fig. 2-1C). The percent of
cholesterol absorbed (40-50%), was unaffected by any of the dietary treatments (Fig. 21 D ).

Naringenin restores glucose homeostasis and insulin sensitivity in Ldlr^mice fed
cholesterol-enriched diets.
Animals fed the HFHC diet were modestly hyperglycemic (7.8 mmol/L) but
significantly hyperinsulinémie (0.77 ng/mL) compared to chow-fed animals (6.5 mmol/L
and 0.2 ng/mL, respectively) (Fig. 2-2A and B). In contrast, naringenin completely
normalized blood glucose and plasma insulin levels (5.8 mmol/L and 0.2 ng/mL,

Figure 2-1. Prevention of diet-induced obesity by naringenin. In two separate
studies, male L d l r mice were placed on diet for 12 weeks, n= 12/group. In study
1, mice were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC
diet supplemented with 3% naringenin. In study 2, mice were fed a low-fat (LF)
diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented with
3% naringenin. (A) Weight gain (g). (B) Caloric intake expressed as
kcal/day/mouse. (C) Adiposity index expressed as epididymal fat pad weight (g)
normalized to body weight (g). (D) Percent intestinal cholesterol absorption,
determined by a dual fecal isotope method. Values are the mean ± SEM.
Different letters are statistically different (P <0.05).
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Figure 2-2. Improved glucose homeostasis and insulin sensitivity in naringenintreated mice. In two separate studies, male Ldlr'- mice were placed on diet for 12
weeks, n= 12/group. In study 1, mice were fed a chow diet, a high-fat/high-cholesterol
(HFHC) diet, or HFHC diet supplemented with 3% naringenin. In study 2, mice were fed
a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented
with 3% naringenin. (A) Fasting blood glucose (mmol/L) was determined using a
glucometer. (B) Plasma insulin concentrations (ng/mL) were measured by ELISA. (C)
Glucose tolerance tests (GTT) were performed after a 6-hour fast by i.p. injection of
15% glucose (1 g/kg body weight), with blood glucose determinations at 0, 15, 30, 45,
60, 90 and 120 minutes post-injection (n= 10-12/group). Inset graph, absolute area
under the curve (AUC), expressed as glucose (mmol/L) x 120 minutes. (D) Insulin
tolerance tests (ITT) were performed after a 6-hour fast by i.p. injection of insulin (0.6
lU/kg body weight), with blood glucose determinations at 0, 15, 30, 45 and 60 minutes
post-injection (n= 10-12/group). Inset graph, area under the curve (AUC), expressed as
glucose (mmol/L) x 60 minutes. Values are the mean ± SEM. Different letters are
statistically different (P <0.05).
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respectively) (Fig. 2-2A and B). The LF, sucrose-containing diet increased fasting blood
glucose (1.3-fold) and plasma insulin levels (2-fold) compared to chow-fed animals. The
addition of cholesterol to the LF diet did not elevate blood glucose or plasma insulin
levels further, compared to LF-fed animals. However naringenin significantly reduced
both parameters to levels observed in chow-fed mice (Fig. 2-2A and B).
An i.p. GTT revealed that naringenin normalized the impaired response to
glucose observed in HFHC-fed animals (Fig. 2-2C). Furthermore, naringenin restored
insulin sensitivity as assessed by an ITT (Fig. 2-2D). No difference was observed in the
glucose excursion or the response to exogenous insulin between LF and LFHC-fed
animals. Naringenin significantly improved glucose and insulin tolerance in LFHC-fed
mice, as determined by the area under the curve (AUC) (Fig. 2-2C and D, inset graphs).
Naringenin attenuates dyslipidemia and hepatic apoB100 overproduction in mice
fed high-cholesterol diets.
As anticipated, both HFHC and LFHC diets significantly increased plasma
cholesterol levels (38 mmol/L and 46 mmol/L, respectively) compared to their respective
controls (Fig. 2-3A). In comparison, naringenin-supplementation to either cholesterol-rich
diet reduced plasma cholesterol by approximately 50% (Fig. 2-3A). The 6-fold increase
in plasma TG concentration observed in HFHC-fed mice was also reduced by 50% with
naringenin (Fig. 2- 3B). Plasma TG increased 4-fold in LF-fed mice compared to chow.
Addition of cholesterol did not further increase plasma TG, however, supplementation of
the LFHC diet with naringenin significantly reduced plasma TG concentrations by 50%
(Fig. 2-3B).

Figure 2-3. Plasma lipid analysis in mice fed a high-cholesterol diet
supplemented with naringenin. In two separate studies, male L d lr'- mice
were placed on diet for 12 weeks, n= 12/group. In study 1, mice were fed a
chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC diet
supplemented with 3% naringenin. In study 2, mice were fed a low-fat (LF)
diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented
with 3% naringenin. (A) and (B) Plasma cholesterol and triglyceride
concentrations (mmol/L). (C) and (D) FPLC was conducted on fresh
plasma samples (n= 3 mice/group) and cholesterol and triglyceride
concentrations were measured in eluted fractions (pg/mL). Values are the
mean ± SEM. Different letters are statistically different (P <0.05).
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Fast performance liquid chromatography (FPLC) on fresh plasma samples
revealed that both cholesterol-enriched diets markedly increased the cholesterol content
of VLDL and LDL particles, and increased VLDL-TG concentrations (HFHC, 4-fold and
LFHC, 2-fold) (Fig. 2-3C and D). In contrast, naringenin attenuated the elevated VLDLand LDL-cholesterol levels, and substantially reduced VLDL-TG, despite the presence of
high or low dietary fat (Fig. 2-3C and D). The cholesterol content of HDL was unaffected
by any of the dietary groups (Fig. 2-3C).
The improvement in dyslipidemia by naringenin treatment was primarily due to a
significant reduction (>50%) in the rate of hepatic TG secretion into plasma compared to
HFHC-fed animals (Fig. 2-4A and B). Upon measurement of hepatic apoB100
production, HFHC-fed mice secreted 2.2-fold more apoB100 into plasma compared to
chow-fed controls (Fig. 2-4C and D), which was significantly reduced by approximately
87% with naringenin supplementation.
A similar trend was observed when naringenin was added to the LFHC diet,
which resulted in a 73% reduction in the rate of TG secretion into plasma (Fig. 2-5A and
B). Similar to HFHC-fed mice (Fig. 2-4D), LFHC-fed animals also displayed an
overproduction of apoB100 containing particles from the liver, which was significantly
attenuated by 71% with the addition of naringenin (Fig. 2-5C and D).

Naringenin supplementation to cholesterol-enriched diets reduces hepatic
steatosis.
In animals fed the HFHC diet, the presence of increased dietary fat and
cholesterol promoted the development of hepatic steatosis, as the livers of these mice
had elevated concentrations of TC, CE, FC and TG (Fig. 2-6A). Naringenin-treatment
significantly prevented the accumulation of both hepatic cholesterol, CE and TG by at
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Figure 2-4. Attenuation of hepatic overproduction of TG and apoB100 in HFHC-fed
animals supplemented with naringenin. Male Ldlr1- mice were placed on diet for 12
weeks and were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC diet
supplemented with 3% naringenin. (A) Plasma triglyceride secretion determined by i.p.
injection of mice with tyloxapol followed by plasma triglyceride measurements (mmol/L) at 0
and 120 minutes (n= 5-6/group/time point). (B) Triglyceride secretion rate expressed as
mmol/L/h. (C) ApoB100 secretion determined by i.p injection of mice with tyloxapol and
[35S]methionine, with plasma samples taken at 60 and 120 minutes post-injection (n= 56/group/time point). VLDL/IDL particles (d= 1.019g/L) were isolated by ultracentrifugation
and subjected to 4.5% SDS-PAGE. (D) ApoB100 production rate expressed as arbitrary
phosphorimager volume units (AU) per hour. Values are the mean ± SEM. Different letters
are statistically different (P <0.05).
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Figure 2-5. A ttenuation o f hepatic overproduction of TG and apoB100 in LFHC-fed
anim als supplem ented w ith naringenin. Male L d l r mice were placed on diet for 12

weeks and were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC diet
supplemented with 3% naringenin. (A) Plasma triglyceride secretion (mmol/L) determined
by i.p. injection of mice with tyloxapol followed by plasma triglyceride measurements at 0
and 120 minutes (n= 5-6/group/time point). (B) Triglyceride secretion rate expressed as
mmol/L/h. (C) ApoBlOO secretion determined by i.p injection of mice with tyloxapol and
[35S]methionine, with plasma samples taken at 60 and 120 minutes post-injection (n= 56/group/time point). VLDL/IDL particles (d= 1.019g/L) were isolated by ultracentrifugation
and subjected to 4.5% SDS-PAGE. (D) ApoBlOO production rate expressed as arbitrary
phosphorimager volume units (AU) per hour. Values are the mean ± SEM. Different letters
are statistically different (P <0.05).

Figure 2-6. Prevention o f hepatic steatosis in HFHC-fed anim als w ith naringenin
treatm ent. Male Ldlr'- mice were placed on diet for 12 weeks (n= 12/group) and were

fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC diet supplemented
with 3% naringenin. (A) Hepatic total cholesterol, cholesteryl ester, free cholesterol
and triglyceride concentrations in pg/mg tissue weight. (B) Representative
photomicrographs, 60x magnification, of liver sections stained with Oil Red O,
hematoxylin, and Hoechst 33258. Top panels are light micrographs and the bottom
panels are fluorescence micrographs following excitation at 493 nm to visualize
neutral lipid droplets (red) and nuclei (blue). Scale bar = 75 pm. Values are the mean
± SEM. Different letters are statistically different (P <0.05).

87

Lipid Mass (pg/mg Tissue)

88

least 50% for each lipid parameter. In representative photomicrographs of liver sections
stained with Oil Red O, which stains neutral lipids red, the greater number of larger lipid
droplets (red staining) in HFHC-fed mice was substantially reduced in naringeninsupplemented animals (Fig. 2-6B).
The LFHC diet induced a similar level of hepatic steatosis as the HFFIC diet,
including hepatic TG (2.5-fold vs. LF diet) and TC (4.5-fold vs. LF diet), despite the lack
of dietary fat (Fig. 2-7A). In contrast, hepatic cholesterol and TG mass were almost
completely normalized to levels observed in LF-fed mice, with the addition of naringenin
to the LFFIC diet (Fig. 2-7B).
N aringenin

does

not

im pact the

expression

of

genes

involved

in

hepatic

cho lesterol m etabolism , w ith the exception of CYP7A1.

The significantly lower hepatic cholesterol mass observed in naringenin-fed mice
suggests that naringenin has the potential to modulate the expression of genes involved
in hepatic cholesterol metabolism. As anticipated, the addition of cholesterol to both a
high-fat, or a low-fat diet, significantly reduced the expression of Srebp-2 and Hmgcr
(approximately 50% for both), and upregulated Cyp7a1 message abundance (1.5- to 2
fold) (Fig. 2-8A and B). Naringenin-supplementation to both cholesterol-enriched diets
had no further effect on cholesterol-induced suppression of Srebp-2 or Hmgcr (Fig. 2-8A
and B). In contrast, naringenin treatment significantly increased the expression of
Cyp7a1 by at least 50%, compared to animals fed the HFHC or LFFIC diet alone (Fig. 28A and B). This suggests that naringenin may reduce hepatic cholesterol mass through
increased conversion of cholesterol to bile acids.
Increased hepatic cholesterol is associated with the upregulation of cholesterol
transporters that efflux cholesterol out of the liver to prevent excessive cholesterol

Figure 2-7. Prevention of hepatic steatosis in LFHC-fed anim als with
naringenin treatm ent. Male Ldlr'- mice were placed on diet for 12 weeks

(n=12/group) and were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet,
or a LFHC diet supplemented with 3% naringenin. (A) Hepatic total cholesterol,
cholesteryl ester, free cholesterol and triglyceride concentrations in pg/mg tissue
weight. (B) Representative photomicrographs, 60x magnification, of liver sections
stained with Oil Red O, hematoxylin, and Hoechst 33258. Top panels are light
micrographs and the bottom panels are fluorescence micrographs following
excitation at 493 nm to visualize neutral lipid droplets (red) and nuclei (blue). Scale
bar = 75 pm. Values are the mean ± SEM. Different letters are statistically different
(P <0.05).
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Figure 2-8. Hepatic cholesterol m etabolism in naringenin-treated m ice, in two
separate studies, male Ldlr1- mice were placed on diet for 12 weeks, n= 12/group. In
study 1, mice were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or
HFHC diet supplemented with 3% naringenin. In study 2, mice were fed a low-fat
(LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented with
3% naringenin. (A) and (B) Expression of Srebp-2, Hmg-CoA Reductase and
Cyp7a1 mRNA relative to Gapdh, and normalized to control values, determined by
qRT-PCR (n= 10-12/group). (C) and (D) Expression of Abcg5, Abcg8, Abcal, and
Abcgl mRNA relative to Gapdh, determined by qRT-PCR (n= 12/group). Values are
the mean ± SEM. Different letters are statistically different (P <0.05).
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accumulation

(30).

Cholesterol-fed

animals

had

significantly

increased

mRNA

abundance of Abcg5, Abcg8, Abcal and Abcgl compared to their respective controls
(Fig. 2-8C and D). However, the addition of naringenin to either the HFHC or LFHC diet
did not affect the expression of Abcg5, Abcg8, or Abcal, although naringenin
significantly prevented the cholesterol-induced expression of hepatic Abcgl (Fig. 2-8C
and D) by 40%, compared to the HFHC or LFHC diet. None of the dietary groups
influenced the expression of hepatic Acatl or Aca/2 mRNA (data not shown).
N aringenin influences the expression of genes involved in hepatic fatty acid
m etabolism .

The 50% reduction in hepatic TG mass observed in naringenin-treated mice
suggests that naringenin impacts the expression of genes that regulate FA synthesis
and/or oxidation. The HFHC and LFHC diets significantly increased the expression of
hepatic Srebp-1c (4-fold and 1.75-fold respectively), compared to controls (Fig. 2-9A and
B). In contrast, naringenin treatment significantly attenuated the increase in Srebp-1c
mRNA by 65% when added to either the HFHC diet or the LFHC diet (Fig. 2-9A and B).
The reduction in hepatic TG by naringenin may also be mediated through an
increase in hepatic FA oxidation. FGF21, PGC-1a, CPT-1a, and ACOX are all key
transcription factors or enzymes involved in regulating mitochondrial and peroxisomal FA
oxidation, as the absence of genes coding for these proteins in mice is known to
promote the development of fatty liver (31-34). Addition of naringenin to a HFHC or
LFHC diet increased the mRNA abundance of Fgf21, Pgc-1a, and Cpt-1a, compared to
the cholesterol-rich diets alone. The greatest naringenin-induced increases were
observed for Fgf21 (5-fold and 2.2-fold, respectively) and Cpt-1 a (1.8-fold and 1.6-fold,
respectively) (Fig. 2-9A and B). The addition of naringenin to the LFHC diet increased
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Figure 2-9. Hepatic fatty acid m etabolism in naringenin-treated mice. In two
separate studies, male Ldlr'- mice were placed on diet for 12 weeks, n= 12/group. In
study 1, mice were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC
diet supplemented with 3% naringenin. In study 2, mice were fed a low-fat (LF) diet, a
low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented with 3% naringenin.
(A) and (B) Expression of Srebp-1c, Fgf21, Pgc-1a, Cpt-1a and Acox mRNA relative to
Gapdh, and normalized to control values, determined by qRT-PCR (n= 10-12/group).
Values are the mean ± SEM. Different letters are statistically different (P <0.05).
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and Acox mRNA 1.2-fold, however, Acox expression was unaffected by the addition of
naringenin to the HFHC diet. None of the diets influenced the expression of hepatic
PpararmRNA (data not shown).
Naringenin prevents the development of hepatic inflammation in cholesterol-fed
mice.
Feeding a high-cholesterol diet to Ldlrv~mice has been demonstrated to induce
hepatic inflammation (10,11). Furthermore, in states of obesity and insulin resistance,
macrophage infiltration into tissues has been shown induce local inflammation,
contributing to systemic inflammation and the potentiation of atherosclerosis (6,7).
Therefore, the abundance of inflammatory cytokines and macrophage markers in the
livers of cholesterol-fed mice were evaluated.
The HFHC diet significantly induced the expression of the inflammatory cytokines
Tnfa and 11-1/3 (5-fold and 2.5-fold, respectively) as well as increased the abundance of
the chemoattractant proteins Mcp-1 and Mip-1a (5-fold and 10-fold, respectively) (Fig. 210A). 11-6 mRNA was unaffected. Additionally, the expression of the macrophage marker
F4/80 and the acute phase protein Saa1/2, were also increased in livers of mice fed the
HFHC-diet (Fig. 2-10A). In liver sections, an increased presence of MAC-2-positive
macrophages was observed in HFHC-fed mice (dark brown stain) (Fig. 2-1 OB).
Conversely, naringenin supplementation to the HFHC diet significantly attenuated the
hepatic expression of Tnfa, 11-1/3, Mcp-1, Mip-1a, by >80% and reduced the message
abundance of F4/80 and Saa1/2 by >50%. In addition, naringenin prevented
macrophage accumulation (MAC-2-positive cells) in the livers of HFHC-fed animals (Fig.
2-1 OB).
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Figure 2-10. Prevention of hepatic inflammation in HFHC-fed mice supplemented
with naringenin. Male Ldlr'- mice were placed on diet for 12 weeks (n= 12/group) and
were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC diet
supplemented with 3% naringenin. (A) Hepatic expression of Tnfa, 11-1/3, 11-6, Mcp-1,
Mip-1a, F4/80 and Saa1/2 mRNA relative to Gapdh, and normalized to control values,
determined by qRT-PCR (n= 10-12/group). (B) Representative photomicrographs of liver,
40x magnification, stained with MAC-2 antibody for the presence of macrophages (dark
brown stain, indicated by arrows). Scale bar =100 pm. Values are the mean ± SEM.
Different letters are statistically different (P <0.05).
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The LFHC diet also stimulated hepatic inflammatory gene expression (Tnfa, II1P, Mcp-1, Mip-1a, and Saa1/2) by 2- to 5-fold, and increased the presence of MAC-2stained macrophages (Fig. 2-11A and B), although the level of inflammation was not
induced to the same extent as animals fed the HFHC diet (Fig. 2-1OA). Supplementation
of naringenin to the LFFIC diet normalized the expression of these hepatic inflammatory
markers (Fig. 2-11 A) and prevented macrophage infiltration into the liver, indicated by
the depletion of MAC-2 positive cells (Fig. 2-11B).
To further explore the role of naringenin in chronic low-grade inflammation
associated with atherosclerosis, the plasma concentration of SAA, which has two
isoforms produced by the liver (SAA1 and 2), were determined. Both the HFHC and
LFHC diets increased plasma SAA1/2 concentrations (12- and 3-fold, respectively),
compared to controls (Fig. 2-12A and B). In contrast, the addition of naringenin to the
cholesterol-enriched diets resulted in a greater than 70% reduction in circulating SAA1/2
levels in both dietary groups (Fig. 2-12A and B). This reduction of inflammatory markers
both at the mRNA and protein level, demonstrates the ability of naringenin to prevent the
local and systemic inflammatory responses associated with cholesterol-rich diets in Ldlrv'
mice.
Naringenin attenuates adipocyte expansion and inflammation induced by high
dietary cholesterol.
During the development of obesity, adipocytes undergo expansion due to
increased accumulation of lipid, and adipocyte hypertrophy is associated with the
development of insulin resistance and inflammation (35). It has been demonstrated that
dietary cholesterol may be a stimulus for macrophage infiltration into adipose tissue
resulting in inflammatory cytokine production and subsequent local inflammation (9). In
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Figure 2-11. Prevention of hepatic inflammation in LFHC-fed mice supplemented
with naringenin. Male Ldlr'- mice were placed on diet for 12 weeks (n= 12/group) and
were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet
supplemented with 3% naringenin. (A) Hepatic expression of Tnfa, ll-1p, 11-6, Mcp-1, Mip1a, F4/80 and Saa1/2 mRNA relative to Gapdh, and normalized to control values,
determined by qRT-PCR (n= 10-12/group). (B) Representative photomicrographs of liver,
40x magnification, stained with MAC-2 antibody for the presence of macrophages (dark
brown stain, indicated by arrows). Scale bar = 100 pm. Values are the mean ± SEM.
Different letters are statistically different (P <0.05).
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Figure 2-12. Reduced plasma serum amyloid A 1/2 concentrations with
naringenin supplementation. In two separate studies, male Ldlr1' mice were
placed on diet for 12 weeks, n= 12/group. In study 1, mice were fed a chow diet,
a high-fat/high-cholesterol (HFHC) diet, or HFHC diet supplemented with 3%
naringenin. In study 2, mice were fed a low-fat (LF) diet, a low-fat/highcholesterol (LFHC) diet, or a LFHC diet supplemented with 3% naringenin. (A)
and (B) Fasted plasma SAA1/2 concentrations (pg/mL) determined by ELISA.
Values are the mean + SEM. Different letters are statistically different (P <0.05).
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order to determine the ability of naringenin to prevent adipocyte expansion, the
adipocyte size distribution and mean adipocyte diameter were calculated from
photomicrographs of epididymal fat pad sections. Animals fed the HFHC diet exhibited
adipocyte hypertrophy, as a greater number of adipocytes were larger in size (91120pm), compared to chow and naringenin-fed mice, whose adipocytes were on
average smaller in diameter (31-90 pm) (Fig. 2-13A). This was reflected as a significant
increase in the mean adipocyte diameter in FlFHC-fed mice (96.5 pm) compared to chow
and naringenin-fed animals (66.2 and 62.8 pm, respectively) (Fig. 2-13B). The addition
of cholesterol to the LF diet did not further impact adipocyte expansion (61-90 pm, mean
89.1 pm) compared to animals fed the LF diet alone (61-90 pm, mean 83.6 pm),
however naringenin treatment markedly reduced adipocyte size (31-60 pm, mean 66.5
pm), similar to animals fed a standard chow diet (Fig. 2-13A and B)
The increased adipose tissue expansion in HFHC-fed animals resulted in a
significant increase in plasma leptin (18-fold), which was normalized with the addition of
naringenin (Fig. 2-13C). The LF and LFHC diets increased plasma leptin levels to the
same extent (7 mmol/L), compared to chow-fed mice (1 mmol/L) (Fig. 2-13C). In
contrast, naringenin supplementation of the LFHC diet significantly reduced plasma
leptin levels by greater than 90% (Fig. 2-13C).
The enlargement of adipocytes in HFHC mice was associated with increased
expression of inflammatory markers including Tnfa, Mcp-1, and F4/80 by 1.5- to 1.8-fold
(Fig. 2-14A). Naringenin completely normalized the expression of these markers of
inflammation. Although a similar pattern of expression was observed for IL-1(3 and Mip1a , differences were not significant. 11-6 mRNA was unaffected. In the presence of a LF
diet, the addition of cholesterol markedly induced the expression of Tnfa, //-7/?and

Figure 2-13. Reduced adipose tissue expansion in cholesterol-fed mice supplemented
with naringenin. In two separate studies, male L d l r mice were placed on diet for 12
weeks, n= 12/group. In study 1, mice were fed a chow diet, a high-fat/high-cholesterol
(HFHC) diet, or HFHC diet supplemented with 3% naringenin. In study 2, mice were fed a
low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet supplemented with
3% naringenin. (A) Adipocyte diameter distribution expressed as the percentage of total
adipocytes counted versus the adipocyte diameter (|am), and (B) mean adipocyte diameter
(^m), was determined from photomicrographs of hematoxylin and eosin-stained sections of
epididymal adipose tissue using Northern Eclipse software (n= 250 adipocytes/group). (C)
Fasted plasma leptin concentrations (ng/mL) determine by ELISA. Values are the mean ±
SEM. Different letters are statistically different (P <0.05).
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Mip-1a, further demonstrating the impact of cholesterol alone (in the absence of dietary
fat), on adipose tissue inflammation (Fig. 2-14B). The addition of naringenin significantly
decreased the level of expression of Tnfa, 11-1/3, IL-6, Mcp-1 and Mip-1a compared to the
LFHC diet alone. F4/80 mRNA was unaffected, suggesting that the infiltration of
macrophages into adipose tissue in LFHC-fed mice was minimal compared to the LF
diet alone (Fig. 2-14B).
Naringenin prevents atherosclerosis and inflammation in the aorta of cholesterolfed mice.
It was important to establish if the ability of naringenin to attenuate plasma and
hepatic lipids, improve glucose and insulin homeostasis, and to reduce local
inflammation could result in protection from atherosclerosis. In cleaned, unstained
aortas, TC mass significantly increased to the same extent (1.5-fold) in both HFHC- and
LFHC-fed animals compared to their respective controls (Fig. 2-15A and B). The HFHCdiet induced a 2-fold greater amount of aortic TG compared to chow-fed mice (4.5 vs.
2.2 pg/mg) (Fig. 2-15A and B). Although the TG content of the aorta was much less in
LF-fed mice compared to chow-fed mice (0.5 vs. 2.2 pg/mg tissue), LFHC increased
aortic TG 3-fold (1.5 pg/mg tissue) compared to LF. In comparison, the addition of
naringenin to either the HFHC or LFHC diet significantly reduced both the increase in
aortic cholesterol and TG, compared to their respective controls (Fig. 2-15A and B).
The dietary cholesterol-induced increase in lipid accumulation correlated with
increased atherosclerotic lesion area within the aortic arch. In animals fed chow and the
LF diet, lesion area was relatively small (1% and 2.2% of total surface area, respectively)
(Fig. 2-16A and 2-17A). However, plaque area was markedly increased in HFHC- (15
fold) and LFHC-fed mice (6-fold) to 13% and 14% of total surface area, respectively (Fig.

Figure 2-14. Reduced adipose tissue inflammation in cholesterol-fed mice
supplemented with naringenin. In two separate studies, male Ldlr'- mice were placed
on diet for 12 weeks, n= 12/group. In study 1, mice were fed a chow diet, a high-fat/highcholesterol (HFHC) diet, or HFHC diet supplemented with 3% naringenin. In study 2,
mice were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet
supplemented with 3% naringenin. (A) and (B) Adipose tissue expression of Tnfa, 11-1/3,
11-6, Mcp-1, Mip-1a, and F4/80 mRNA relative to Gapdh, and normalized to control
values, determined by qRT-PCR (n= 8/group). Values are the mean ± SEM. Different
letters are statistically different (P <0.05).
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Figure 2-15. Prevention of aortic lipid accumulation in cholesterol-fed mice
treated with naringenin. In two separate studies, male Ldlr1- mice were placed on diet
for 12 weeks, n= 12/group. In study 1, mice were fed a chow diet, a high-fat/highcholesterol (HFHC) diet, or HFHC diet supplemented with 3% naringenin. In study 2,
mice were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet
supplemented with 3% naringenin. (A) and (B) Total cholesterol and triglyceride
concentrations (pg/mg tissue weight) in cleaned, whole aortas (n= 6-8/group). Values
are the mean ± SEM. Different letters are statistically different (P <0.05).
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Figure 2-16. Prevention of atherosclerosis in HFHC-fed mice in the aortic arch by
naringenin supplementation. Male L d l r mice were placed on diet for 12 weeks (n=
12/group) and were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC
diet supplemented with 3% naringenin. (A) Percentage of atherosclerosis development in
the aortic arch, calculated as the Sudan IV-stained plaque area normalized to the total
surface area shown (ascending and descending aorta). Values from individual mice are
represented by symbols and the mean lesion area is depicted as a single horizontal line
(n= 6-8/group). (B) Representative photomicrographs of atherosclerotic lesions in the en
face preparation of the aortic arch stained with Sudan IV. Values are the mean ± SEM.
Different letters are statistically different (P <0.05).
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Figure 2-17. Prevention of atherosclerosis in LFHC-fed mice in the aortic arch by
naringenin supplementation. Male L d l r mice were placed on diet for 12 weeks (n=
12/group) and were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a
LFHC diet supplemented with 3% naringenin. (A) Percentage of atherosclerosis
development in the aortic arch, calculated as the Sudan IV-stained plaque area
normalized to the total surface area shown (ascending and descending aorta). Values
from individual mice are represented by symbols and the mean lesion area is depicted
as a single horizontal line (n= 6-8/group). (B) Representative photomicrographs of
atherosclerotic lesions in the en face preparation of the aortic arch stained with Sudan
IV. Values are the mean ± SEM. Different letters are statistically different (P <0.05).
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2-16A and 2-17A). Naringenin supplementation to the HFHC or LFHC diet reduced
plaque area by 43% and 47% respectively (Fig. 2-16A and 2-17A), which is depicted in
representative photographs of the aortic arch stained with Sudan IV (Fig. 2-16B and 217B).
To establish the role of naringenin treatment on inflammation within the aorta, the
full-length aorta was excised from mice fed chow, HFHC and HFHC plus naringenin, and
mRNA was isolated for qRT-PCR analysis of inflammatory cytokines. In concert with the
increased lipid load in the aorta induced by the HFHC diet (Fig. 2-15A), the expression
of the inflammatory markers Tnfa, 11-1/3, and Mcp-1 were significantly increased,
approximately 2-fold (Fig. 2-18 A-C). Conversely, naringenin supplementation of the
HFHC diet normalized inflammatory cytokine expression (Fig. 2-18 A-C).
Naringenin prevents atherosclerosis and alters plaque morphology in the aortic
root of cholesterol-fed mice.
Atherosclerotic plaque was also quantitated in serial sections of the aortic root
stained with Oil Red O. In mice fed chow and the LF diet, plaque areas were relatively
small, 0.15 and 0.64 and pm2 X 105, respectively. Both the HFHC and LFHC diets
significantly increased Oil Red O-stained plaque area in the aortic root (26- and 7.5-fold)
to approximately the same extent 4.7 pm2 X 105for both, demonstrated in representative
photomicrographs (Fig. 2-19 and 2-20). Conversely, naringenin treatment prevented the
development of stained lesion area by approximately 50% in the aortic root from both
HFHC and LFHC-fed mice (Fig. 2-19 and 2-20).

110

x
Q. •42—* 3
< c
CD o
o
5>
w v+o—
CD
CD u 2
)
C O
c
CO
o x:
o
<
z
Cd
E

I

Q

IC h o w

^■ H F H C
i-

I H F H C + 3 % N a rin g e n in

i—

-t— ‘

a

1

0

Figure 2-18. Prevention of inflammation in the aorta by naringenin
supplementation to the HFHC diet. Male Ldlr1- mice were fed a chow diet, a highfat/high-cholesterol (HFHC) diet, or HFHC diet supplemented with 3% naringenin for 12
weeks. (A-C) Aortic expression of Tnfa, 11-1J3, and Mcp-1 mRNA relative to Gapdh, and
normalized to control values, determined by qRT-PCR (n= 6-7/group). Values are the
mean ± SEM. Different letters are statistically different (P <0.05).
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Figure 2-19. Prevention of atherosclerosis in HFHC-fed animals in the aortic root
by naringenin treatment. Male Ldlr1- mice were placed on diet for 12 weeks (n=
12/group) and were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or HFHC
diet supplemented with 3% naringenin. (A) Plaque area (pm2x 105) determined in serial
sections (10 pm apart) of the aortic root stained with Oil Red O (n= 8-10/group). Values
from individual mice are represented by symbols and the mean lesion area is depicted
as a single horizontal line. (B) Representative photomicrographs of the aortic root
stained with Oil Red O and counterstained with hematoxylin. Scale bar = 120 pm.
Values are the mean ± SEM. Different letters are statistically different (P <0.05).
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Figure 2-20. Prevention of atherosclerosis in LFHC-fed animals in the aortic root
by naringenin treatment. Male Ldlr'- mice were placed on diet for 12 weeks (n=
12/group) and were fed a low-fat (LF) diet, a low-fat/high-cholesterol (LFHC) diet, or a
LFHC diet supplemented with 3% naringenin. (A) Plaque area (pm2x 105) determined in
serial sections (10pm apart) of the aortic root stained with Oil Red O (n= 8-10/group).
Values from individual mice are represented by symbols and the mean lesion area is
depicted as a single horizontal line. (B) Representative photomicrographs of the aortic
root stained with Oil Red O and counterstained with hematoxylin. Scale bar = 120 pm.
Values are the mean ± SEM. Different letters are statistically different (P <0.05).
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Plaque morphology was greatly impacted by both the HFHC and LFHC diets.
The increase in Oil Red O-stained lesion area was associated with MOMA-2 staining,
indicating that lipid-rich, macrophage foam cells were present in the lesions (Fig. 2-21AB and Fig. 2-22A-B). Plaques that developed in both cholesterol-fed groups also stained
positively for collagen, which corresponded to the extent of SMC a-actin-stained area,
suggesting that smooth muscle cell accumulation within lesions contributed to the
secretion of collagen fibrils (Fig. 2-21A-B and Fig. 2-22A-B). Quantitatively, while both
cholesterol-rich diets significantly increased plaque area, compared to chow or LF, both
diets induced lesions in which the percentage of stained lesion area occupied by MOMA2 was lower, with a concomitant increase in the percentage of area occupied by
trichrome-stained collagen and SMC a-actin material (Fig 2-21C and 2-22C).
Collectively, these data suggest that cholesterol feeding, even in the absence of dietary
fat, promotes the development of complex atherosclerotic lesions that are not only rich
lipid but also in collagen, representing a more fibrous phenotype.
In contrast, supplementation of either cholesterol-enriched diet with naringenin
not only resulted in markedly fewer lesions, morphometric analyses revealed that
plaques were mostly rich in lipid, which corresponds to MOMA-2-stained macrophages
(Fig. 2-21 and 2-22). Furthermore, these lesions contain a reduced abundance of
collagen and SMC a-actin, and can therefore be characterized as lesions in the early
stages of development (Fig. 2-21 and 2-22). Therefore, these studies demonstrate that
in addition to reducing the total plaque area, naringenin treatment can also prevent
plaque progression to more complicated lesions.

Figure 2-21. Atherosclerotic plaque morphology in HFHC-fed animals
supplemented with naringenin. Male Ldlr'- mice were placed on diet for 12 weeks (n=
12/group) and were fed a chow diet, a high-fat/high-cholesterol (HFHC) diet, or a HFHC
diet supplemented with 3% naringenin. (A) and (B) Photomicrographs of serial sections
of the aortic root stained with Oil Red O and hematoxylin, monocyte/macrophage
antibody-2 (MOMA-2), trichrome or antibody to smooth muscle cell (SMC) a-actin. Size
bar = 500 pm (A) and 250 pm (B). Arrows indicate positive stain for lipid (Oil Red O),
macrophages (MOMA-2), collagen (trichrome) and smooth muscle cells (SMC a-actin).
(C) Graphical representation of the MOMA-2, collagen (from trichrome), and SMC aactin-positively stained area expressed as a percentage of total plaque area. Values are
the mean ± SEM. Different letters are statistically different (P <0.05).
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Figure 2-22. Atherosclerotic plaque morphology in LFHC-fed animals supplemented
with naringenin. Male Ldlr1' mice were placed on diet for 12 weeks (n= 12/group) and
were fed a low-fat diet (LF), a low-fat/high-cholesterol (LFHC) diet, or a LFHC diet
supplemented with 3% naringenin. (A) and (B) Photomicrographs of serial sections of the
aortic root stained with Oil Red O and hematoxylin, monocyte/macrophage antibody-2
(MOMA-2), trichrome or antibody to smooth muscle cell (SMC) a-actin. Size bar = 500 pm
(A) and 250 pm (B). Arrows indicate positive stain for lipid (Oil Red O), macrophages
(MOMA-2), collagen (trichrome) and smooth muscle cells (SMC a-actin). (C) Graphical
representation of the MOMA-2, collagen (from trichrome), and SMC a-actin-positively
stained area expressed as a percentage of stained lesion area. Values are the mean ±
SEM. Different letters are statistically different (P <0.05).
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Naringenin prevents neutral lipid accumulation and inflammation in mouse
peritoneal macrophages.
Recently, Li et al showed that elicited peritoneal macrophages from LdlrA mice
fed a high-fat, high-cholesterol diet could be used as an in vivo model of macrophage
foam cell formation. Peritoneal macrophages from high-fat fed animals take up a
significant amount of lipid compared to animals fed a standard chow diet (36). Therefore,
we investigated whether the ability of naringenin to prevent atherosclerosis in HFHC-fed
mice was mediated, in part, through a direct effect on lipid uptake, and the expression of
inflammatory markers at the level of the macrophage foam cell.
After a 12-week feeding period, quantitative lipid measurements revealed that
elicited peritoneal macrophages from HFHC-fed animals accumulated significantly more
TC (2-fold), CE (15-fold) and TG (4-fold), compared to macrophages from mice fed a
chow diet (Fig. 2-23A). Increased cellular lipid correlated with markedly increased Oil
Red O stained cellular lipid droplets (Fig. 2-23B).

In comparison, peritoneal

macrophages isolated from naringenin-treated animals demonstrated a 50%, 70% and
60% reduction in TC, CE and TG mass, respectively, which correlated with a significant
reduction in neutral lipid droplets (Fig. 2-23A and B).
Analysis of inflammatory cytokine expression in peritoneal macrophages
revealed no induction of expression with the HFHC-diet. However, naringenin
significantly attenuated the expression of Tnfa, Mcp-1, and Mip-1a, (-30 to -50%)
compared to HFHC-fed animals (Fig. 2-23B), further demonstrating the ability of
naringenin to attenuate the inflammatory response.

Figure 2-23. Prevention of neutral lipid accumulation and inflammation in mouse
peritoneal macrophages by naringenin. Male Ldlr'- mice were fed a chow diet, a highfat/high-cholesterol (HFHC) diet, or HFHC diet supplemented with 3% naringenin for 12
weeks, n= 16/group. After 12 weeks, mice were injected i.p. with thioglycollate and 5 days
later peritoneal macrophages were harvested for analysis. (A) Cellular total cholesterol,
cholesteryl ester and triglyceride concentrations (pg/mg cell protein). (B) Representative
photomicrographs of peritoneal macrophages, stained with Oil Red O and hematoxylin, 40x
magnification. Scale bar = 100 pm. (C) Mouse peritoneal macrophage expression of Tnfa, II1/3, 11-6, Mcp-1, and Mip-1a mRNA relative to Gapdh, and normalized to control values,
determined by qRT-PCR (n= 10-14/group). Values are the mean ± SEM. Different letters are
statistically different (P <0.05).
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2.4 Discussion
Hypercholesterolemia is a significant risk factor for the development of
atherosclerosis (37). In Ldlrm
/' mice, addition of cholesterol to a high-fat diet can intensify
the dyslipidemia and inflammatory responses in adipose tissue and liver, which may
potentiate atherogenesis (8,9,11). Furthermore, increasing the cholesterol content of
diets high in simple carbohydrates, such as sucrose, promotes hypercholesterolemia
and atherosclerosis in Ldlr* mice (23). Previously we reported that the citrus flavonoid
naringenin can prevent apoB100 secretion from human HepG2 hepatocytes, through
modulation of the phosphatidylinositol 3-kinase (PI3-K) and mitogen-activated protein
kinase extracellular related kinase 1/2 (MAPKerk) pathways (27,38-40). Moreover, the
ability of naringenin to reduce apoB100 production occurs independent of the insulin
receptor (41), thereby identifying a novel molecule that functions similar to, and
enhances the effects of insulin. In Ldlr* mice fed a high-fat, low-cholesterol diet, a model
of diet-induced insulin resistance and obesity, supplementation with naringenin
prevented dyslipidemia, and obesity, and improved insulin sensitivity, contributing to a
reduction in atherosclerosis (21,22). However, the ability of naringenin to prevent
metabolic dysfunction, the inflammatory response, and atherogenesis induced by
cholesterol-rich diets, has not yet been explored.
In the present study, we demonstrate that the addition of naringenin to a
cholesterol-supplemented, high- or low-fat diet prevents obesity, glucose intolerance and
insulin resistance. Naringenin markedly attenuates dyslipidemia, hepatic steatosis and
atherosclerosis. We reveal for the first time that naringenin completely prevents the
cholesterol-induced inflammatory response in liver, adipose tissue and aorta, which
collectively contribute to the significant attenuation of atherosclerosis.
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The provision of diets to mice that are rich in fat and/or cholesterol induces
hepatic steatosis (10,11), which is primarily a consequence of both increased SREBPIcinduced lipogenesis driven primarily by hyperinsulinemia, and reduced FA oxidation
(22,42). Similarly, diets rich in simple carbohydrates, such as fructose and sucrose, also
induce hepatic lipid accumulation in rodents (43,44). Fructose feeding in rats increased
the hepatic activity of the carbohydrate response element-binding protein (ChREBP),
and nuclear SREBP-1, demonstrating that the excess hepatic lipid accumulation is
primarily the consequence of lipogenesis (45). Consistent with these reports, we show
that the HFHC, LF and LFHC diets significantly increased both hepatic TG and
cholesterol accumulation, compared to chow-fed animals. Surprisingly, addition of
cholesterol to the LF diet resulted in a further induction of hepatic TG. This occurred in
the absence of excess dietary fat and corresponded to an additional increase in hepatic
Srebp-1c expression, even though hyperinsulinemia was not further elevated in LFHCfed animals. This reflects the impact of dietary cholesterol on LXR-stimulated SREBP-1 c
induction of FA synthesis in mice (46).
Despite the potent induction of hepatic steatosis in animals fed both cholesterolrich diets, naringenin markedly prevented hepatic lipid accumulation, which correlated
with changes in gene expression. Naringenin reduced the abundance of hepatic Srebp1c, and increased the expression of Fgf21, Pgc-1a and Cpt-1a. These changes in
hepatic gene expression were consistent with our previous studies, in which the primary
effect of naringenin, when added to a high-fat, low cholesterol diet, decreased insulinstimulated Srebp-1c, and increased Pgc-1a and Cpt-1a expression. This led to
decreased FA and TG synthesis, and increased hepatic FA oxidation, thereby reducing
hepatic steatosis (22). We now demonstrate that naringenin maintains the ability to
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decrease hepatic TG following the addition of cholesterol to a high-fat diet. Furthermore,
the current study makes the novel observation that naringenin prevents hyperinsulinemia
and normalizes liver TG in mice fed a cholesterol-containing, low-fat, high-sucrose diet
(LFHC), a diet that primarily increases hepatic TG through the induction of SREBPIcmediated FA synthesis. Recently, adenovirus-mediated hepatic expression of a
permanently active mutant form of Cpt-1a to high-fat fed obese mice, resulted in
increased hepatic FA oxidation, thereby reducing hepatic TG content and ameliorating
insulin resistance (47). This implies that the ability of naringenin to upregulate the
expression of the FA oxidation signaling program, and to inhibit Srebp7c-mediated
lipogenesis, not only protects from fatty liver, but contributes to the decrease in hepatic
TG production, and the normalization of insulin sensitivity.
The naringenin-induced changes in hepatic expression of genes involved in FA
metabolism, do not fully explain the marked decrease in hepatic cholesterol
concentrations following the addition of naringenin to either cholesterol-rich diet.
Naringenin did not further affect the cholesterol-induced inhibition of Hmgcr expression,
or further upregulate the cholesterol efflux transporters Abcal, Abcg5 or Abcg8.
Although naringenin prevented the cholesterol-induced increase in Abcgl mRNA, the
contribution of this effect to the prevention of hepatic CE accumulation is not clear.
However, naringenin markedly enhanced the expression of hepatic Cyp7a1, a ratelimiting enzyme that catalyzes the conversion of cholesterol to bile acids (48).
Transgenic mice overexpressing Cyp7a1 (Cyp7a1-tg), fed a high-fat, cholesterolcontaining diet, demonstrated a significant reduction in hepatic cholesterol and TG, due
to enhanced bile acid synthesis and secretion (49). Cyp7a1-tg mice were protected from
diet-induced adiposity, and exhibited improved insulin sensitivity compared to wildtype
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animals (49). Therefore, the naringenin-induced increase in Cyp7a1 message
abundance represents a potential mechanism by which naringenin alleviates hepatic
cholesterol load, thereby contributing to the improvement in overall metabolic function.
Whether the effect of naringenin on Cyp7a1 is direct or indirect requires further
investigation.
Hepatic apoB100 overproduction is a feature of the dyslipidemia associated with
insulin resistance (4). Furthermore, increased hepatic lipid drives hepatic VLDL
production (50). Consistent with the enhanced liver lipid accumulation in HFHC- and
LFHC-fed animals, these mice demonstrate an over-production of apoBIOO-containing
particles, and enhanced TG secretion into plasma resulting in a significant contribution to
the increased plasma lipid levels. Although the LFHC diet increased hepatic TG levels
compared to the LF diet alone, there was no concomitant increase in plasma TG
compared to LF-fed animals. This is consistent with findings from Teupser et al., where
the addition of cholesterol to the same LF diet did not increase plasma TG, compared to
the LF diet without cholesterol. Hepatic cholesterol was also markedly increased by the
addition of cholesterol to the LF-diet, however hepatic TG mass was not reported in this
study (23). These observations suggest that addition of cholesterol to the LF sucrosecontaining diet results in differences in the mobilization of hepatic TG for VLDL
secretion, or a more efficient removal of TG from secreted VLDL particles. Further
research is required to investigate these possible mechanisms.

Nevertheless,

supplementation of either cholesterol-rich diet with naringenin markedly decreases
apoB100 secretion, concomitant with the striking reduction in hepatic TG and
cholesterol.
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Cholesterol-feeding

has

recently been

linked to the chronic

low-grade

inflammation associated with obesity and atherosclerosis. In particular, increased dietary
cholesterol promotes macrophage infiltration and stimulates the inflammatory response
in both liver, and adipose tissue (9,11). These findings were confirmed in our studies, as
HFHC-fed mice had increased hepatic macrophage infiltration, a marked elevation of
hepatic and adipose inflammatory markers, and enhanced plasma SAA1/2 levels
compared to chow-fed mice. Furthermore, our studies clearly revealed the inflammatory
capability of dietary cholesterol, even in the absence of dietary fat. The addition of
cholesterol to the LF diet also stimulated the inflammatory response in the liver and
adipose tissue however the magnitude of effect was not as great as in HFHC-fed
animals. It is important to mention that although both cholesterol-containing diets
increased inflammatory cytokine expression, it is unclear which cell type, Kupffer cell,
infiltrating macrophage or adipocyte, contributed to the expression of these genes in the
liver and adipose, respectively, as each of these cell types can participate in the
inflammatory response (35,51).
In

contrast

to

animals

fed

the

HFHC

and

LFHC

diets,

naringenin-

supplementation substantially reduced macrophage infiltration in liver and the
expression of inflammatory cytokines in both liver and adipose tissue. The mechanism
by which naringenin alleviates these inflammatory processes could be through its ability
to reduce cholesterol exposure and FA-induced lipotoxicity. In ob/ob mice, cholesterol
feeding was associated with increased hepatic FC in mitochondria, which depleted
mitochondrial glutathione, thereby sensitizing the liver to TNFcr- and Fas-mediated
steatohepatitis. Saturated FAs have also been linked to inflammation, as in vitro
incubation of both adipocytes and macrophages with the saturated FA palmitate,
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increased inflammatory cytokine secretion via activation of the toll-like receptor 4 (TLR4)
(52). Furthermore, in vivo models of obesity, including the HFHC diet in the present
study, that induce macrophage accumulation into adipose tissue, involve the use of highfat diets that are rich in saturated FAs (53-55). Therefore, the ability of naringenin to
prevent the detrimental effects of excess lipid accumulation, via a reduction in hepatic
steatosis and adipose tissue accumulation, may contribute to the decrease in
inflammation. Our results with naringenin are consistent with high-fat fed mice over
expressing hepatic Cpt-1a to induce FA oxidation, which significantly reduced hepatic
steatosis and adipocyte hypertrophy, thereby attenuating Tnfa and Mcp-1 expression in
both liver and adipose tissue (47).
The chronic, low-grade inflammation in adipose tissue associated with obesity is
thought to contribute to the development of insulin resistance (53). In obese ob/ob mice,
macrophage

infiltration

into

adipose

tissue

precedes

the

development

of

hyperinsulinemia, suggesting that obesity-related insulin resistance may be initiated, in
part, by chronic inflammation in adipose tissue (53). In vitro, TNFa has been shown to
inhibit insulin signaling, as the chronic exposure of low concentrations of TNFa to
adipocytes inhibits insulin-stimulated tyrosine phosphorylation of the insulin receptor and
insulin receptor substrate-1 (IRS-1), leading to reduced glucose uptake (56). In the
present study, enhanced adipose tissue accumulation in HFHC-fed mice was associated
with impaired insulin sensitivity and glucose intolerance, consistent with previous reports
in Ldlrv' mice fed diets high in fat and cholesterol (9). It is also clear from our study that
compared to a chow diet, the LF-sucrose-containing diet increases adiposity and fasting
hyperinsulinemia, and impairs glucose tolerance and insulin sensitivity. Unexpectedly,
the addition of cholesterol to the LF diet did not further increase plasma insulin, or impair
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glucose tolerance. This was despite significantly increased adipose tissue inflammation,
although the extent of the LFHC diet-induced inflammatory response was much less
than that of the HFHC diet. These findings suggest that increased dietary cholesterol, in
the presence of dietary fat, intensifies adipose tissue inflammation, thereby potentiating
insulin resistance. However in the LFHC-fed mice, the adipose tissue, which
accumulates primarily in response to endogenous FA synthesis, is resistant to
cholesterol-induced inflammation and perhaps the inflammatory response is insufficient
to exacerbate insulin resistance.
The ability of naringenin to prevent obesity and cholesterol-induced inflammation,
may therefore contribute to the improvement in glucose homeostasis and insulin
sensitivity. A similar phenomenon was observed in high-fat fed mice lacking TNFa
expression in adipose tissue macrophages, which prevented adipose accumulation and
enhanced insulin sensitivity (57). In vitro administration of resveratrol, a polyphenolic
molecule, to 3T3-L1 adipocytes prevented the expression of inflammatory adipokines
and improved insulin signaling by increasing the IRS-1 protein levels (58). Further
mechanistic studies are required to define the contribution of the naringenin-induced
prevention of adiposity and adipose inflammatory response, to the prevention of insulin
resistance.
Obesity-associated chronic low-grade inflammation is thought be a risk factor for
cardiovascular disease (9,59,60), and increased dietary cholesterol potentiates the
atherogenic

response

(8,23).

In HFHC- and LFHC-fed mice,

increased

local

inflammation in liver and adipose tissue, combined with the development of systemic
inflammation, likely contributed to accelerated atherogenesis. These mice developed
complex atherosclerotic lesions in the aortic root and throughout the aorta. Our results
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are consistent with studies in mice and humans demonstrating that high dietary
cholesterol enhances circulating levels of the inflammatory mediators SAA and CRP,
which is associated with increased atherosclerosis (9,60,61). In naringenin-treated mice
the reduced dyslipidemia, improved insulin sensitivity, and decreased hepatic, adipose,
and

systemic

inflammation,

collectively

contributed

to

a

40-50%

reduction

atherosclerosis.
Supplementation of naringenin to cholesterol-rich diets not only prevented lipid
accumulation but also the expression of inflammatory cytokines within the aorta,
demonstrating that the anti-inflammatory properties of naringenin extend to the arterial
wall. Therefore, it was important to establish if naringenin could mediate these potent
anti-inflammatory effects at the cellular level, in particular, on the macrophage foam cell,
which plays an integral role in mediating the inflammatory response associated with
atherogenesis (62). Elicited peritoneal macrophages from HFHC-fed mice, an in vivo
model of foam cell formation (36), were significantly enriched in cellular cholesterol and
TG. Paradoxically, lipid accumulation was not associated with increased expression of
inflammatory markers. This implies that lipid-loading of these cells within the peritoneum
is not linked to inflammation. Despite this finding, naringenin significantly attenuated the
lipid content and the expression of Tnfa, Mcp-1 and Mip-1a. These data suggest that the
mechanism by which naringenin attenuates inflammation may not only be through its
lipid-lowering capability, but also via a direct effect on inflammatory signaling. Several in
vitro studies have reported that naringenin modulates inflammation in macrophages and
human airway epithelial cells, through inhibition of NF-xb and AP-1 signaling, two
important pathways that mediate the inflammatory response (19,20). However, direct
experimental evidence is required to elucidate the precise mechanism by which
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naringenin prevents inflammatory signaling, not only in macrophages, but also in liver
and adipose tissue.
Consistent with our previously published data in HFLC-fed mice (21), naringenin
altered the composition of atherosclerotic lesions. In HFHC and LFHC-fed animals,
atherogenesis is accelerated compared to chow; lesions consisted not only of lipid-laden
macrophage foam cells, but also contained an abundance of collagen, which was
associated with increased presence of SMC a-actin. This suggests that cholesterol
feeding induces the formation of complex lesions with a more fibrous phenotype,
consistent with human type IV or V lesions (63). In comparison, lesions from naringenintreated mice displayed reduced collagen, and SMC a-actin content, but increased
macrophage presence compared to HFHC and LFHC-fed animals. This suggests that
the atherosclerotic lesions in the aortic sinus from naringenin-treated mice were less
mature, consisting of mostly lipid-laden macrophages, in concert with human type II and
III lesions. Therefore, in a model in which atherogenesis is accelerated by dietary
cholesterol, naringenin has the ability to prevent the progression of atherosclerotic
lesions to more complex phenotypes.
In conclusion, these studies demonstrate the ability of naringenin to prevent
metabolic dysregulation induced by cholesterol-feeding both in the presence and
absence of dietary fat. Naringenin’s potent lipid lowering property contributes to reduced
hyperlipidemia and increased insulin sensitivity. For the first time, these studies
demonstrate the ability of naringenin to prevent the cholesterol-induced inflammation
associated with obesity and atherosclerosis. These studies also highlight the possibility
that naringenin has a direct effect on the inflammatory processes that potentiate
atherogenesis. Therefore, the potent pharmacological properties of naringenin provide
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insight into possible therapeutic targets for preventing atherosclerosis associated with
metabolic dysrégulation.
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CHAPTER 3
Naringenin prevents metabolic dysregulation in Fgf21'/' mice
3.1 Introduction
A protein called fibroblast growth factor 21 (FGF21), a member of the FGF
superfamily (1), has recently been identified as an important regulator of energy
availability and the metabolic adaptation to fasting (2). FGF21 is expressed in the liver,
adipose tissue, pancreas, and muscle (2). In contrast to classical FGFs, FGF21 lacks
the conventional heparin-binding domain, resulting in low affinity for cell-surface FGF
receptors, therefore allowing FGF21 to diffuse from its site of production and act on
distal tissues, in an endocrine-like manner (3). Although FGF21 engages the FGF
receptor (FGFR), efficient receptor activation requires its obligate co-receptor (3-Klotho
(4,5). As the tissue-specific activity of (3-Klotho is largely restricted to pancreas, adipose
tissue and liver, (3-Klotho expression, and not FGFRs, define the tissue selectivity of
FGF21 action and determine its distinct physiological roles (4,5).
FGF21 expression is induced by fasting, and is regulated, in part, by the
transcription factor peroxisome proliferator-activated receptor a (PPARa) (6). FGF21
induces hepatic expression of PPAR gamma co-activator-1a (PGC-1a), a potent
regulator of genes involved in hepatic fatty acid (FA) oxidation and ketogenesis (7). The
importance of FGF21 in regulating energy and lipid metabolism was demonstrated by
the administration of recombinant FGF21 protein to obese ob/ob mice or to high-fat fed
C57BI/6 mice. FGF21 reduced hepatic steatosis, improved insulin sensitivity and
enhanced energy expenditure (8,9). Pharmacological administration of FGF21 to
diabetic monkeys improves glucose tolerance, reduces plasma insulin and triglyceride
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(TG) concentrations, and prevents hepatic steatosis (10). Furthermore, transgenic mice
over expressing hepatic FGF21 are lean, and are protected from high-fat diet-induced
insulin resistance (9).
We previously reported that Ldlr'A mice fed a high-fat diet supplemented with the
citrus flavonoid naringenin increased the hepatic expression of Pgc-1a and carnitine
palmitoyltransferase 1a (cpt-1a), leading to increased FA oxidation (11). Naringenin also
prevents adiposity and improves insulin sensitivity (11). Furthermore, naringenin
significantly increases the hepatic expression of Fgf21 in Z_c//r'A mice fed a high-fat, high
cholesterol (HFHC) diet or a low-fat, high-cholesterol (LFHC) diet for 12 weeks (Chapter
2, Fig. 2-9). Collectively, these results in naringenin-treated mice are similar to the
metabolic effects currently established for FGF21.
The provision of ketogenic diets (high-fat, low carbohydrate) to mice creates a
model of prolonged fasting and results in weight loss, improved glucose tolerance, and
dramatic changes in the expression of hepatic genes that regulate energy utilization
(12). Mice lacking FGF21 through genetic deletion (Fgf21'A) have an atypical response
to ketogenic diets. These mice gain weight, become susceptible to impaired
ketogenesis, develop fatty liver, and their ability to mobilize and utilize lipids is blunted
(12). Based on these findings, it would be predicted that FGF21 plays an important role
in models of diet-induced obesity and insulin resistance. In order to further elucidate the
function of FGF21, we examined the metabolic impact of a high-fat, western diet in
Fgf21'/' mice. Furthermore, we hypothesized that the mechanism for protection from
metabolic dysregulation by naringenin involved activation of FGF21.
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In these studies, we established that Fgf21'/' mice represent a unique model of
diet-induced obesity and metabolic dysregulation. The absence of FGF21 enhances the
response to a high-fat diet. Adipose tissue accumulation and hepatic steatosis are more
severe in western-fed Fgf21'/' mice relative to wild-type (WT) mice. Furthermore, Fgf21/
mice fed a western diet display significant hyperinsulinemia and impaired insulin
tolerance compared to western-fed WT mice, demonstrating the role of FGF21 in
glucose homeostasis.
Using the Fgf21'/' mouse model, we have determined that naringenin can protect
against the development of diet-induced metabolic dysfunction, including the prevention
of obesity and hepatic steatosis, even in the absence of FGF21. We conclude that the
mechanism of action of naringenin does not require the expression of FGF21.

3.2 Research Design and Methods
3.2.1 Animals and Diets
Male C57BI/6 mice (Jackson Laboratory, Bar Harbour, ME, USA), and Fgf21'/'
mice on a C57BI/6 background (generously provided by Dr. Chris Pin, The University of
Western Ontario (12,13)), at 8-12 weeks of age, were housed singly, on a 12-hour
light/dark cycle, at 23°C. All studies were approved by the Animal Care and Use
Subcommittee at the University of Western Ontario. Animals were fed ad libitum for
sixteen weeks (n=6-8/group) either a standard chow diet (14% kcal fat, TD8604, Harlan
Teklad, Madison, Wl), a high-fat, western diet (42% kcal fat, 0.05% wt/wt cholesterol,
TD96125, Harland Teklad), or a western diet supplemented with 3% wt/wt naringenin
(Sigma-Aldrich, St. Louis, MO). Food intake and body weight measurements were
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conducted three times per week. Caloric intake was calculated as weight of food eaten
(g) multiplied by the caloric content of each diet (chow; 3.1 kcal/g, western; 4.5 kcal/g).
Mice were fasted for 4 hours before metabolic studies and prior to sacrifice.
3.2.2 Plasma Analysis
Mice were euthanized by C 02 inhalation and cardiac puncture was conducted to
collect blood using an EDTA-syringe. Blood was centrifuged at 14,000 rpm for 5 minutes
at 4°C to separate the plasma, which was stored at -20°C for further use. Plasma insulin
(Alpco Diagnostics, Windham, NH, USA) was determined on samples by a mousespecific ELISA. Plasma triglyceride (TG), total cholesterol (TC) (Roche Diagnostics,
Laval, Canada) and plasma free fatty acids (FFA) were measured enzymatically
(11,14,15).
3.2.3 Tissue Lipids
Liver and quadriceps were removed, weighed, snap frozen in liquid nitrogen and
stored at -80°C. Hepatic and muscle lipid were extracted using choloroform:methanol
(2:1; v/v) and were quantitated as described previously (11,14,15) and in Chapter 2. [3H]cholesterol or [3H]-triglyceride were added to each sample to assess recovery. TG, TC,
and free cholesterol (FC) were determined by enzymatic, colorimetric assays (TG,
Roche Diagnostics; TC and FC; Wako) (11,14,15)
3.2.4 Glucose and Insulin Tolerance Tests
For glucose tolerance tests (GTT), mice were fasted for 4 hours and
administered by gavage a 20% D-glucose solution in 0.9% NaCI at a dose of 1 g/kg
body weight. Blood was collected from the saphenous vein and blood glucose was
measured by glucometer (Acenscia Elite, Bayer Healthcare, Toronto, ON, Canada) at 0,
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15, 30, 45, 60, 90, and 120 minutes post-gavage. For insulin tolerance tests (ITT), non
fasted mice were injected intraperitoneally (i.p.) with 0.6 lU/kg Novolin ge Toronto (Novo
Nordisk, Mississauga, ON, Canada). Blood was collected from the saphenous vein and
blood glucose was measured as stated above every 15 minutes for one hour (11,14,15).
3.2.5 RNA Isolation and Quantitative Real-Time PCR
RNA was isolated from the liver using the TRIzol reagent (Invitrogen) and mRNA
concentrations quantitated using an ND-1000 nanodrop spectrophotometer (Thermo
Fisher Scientific, Nepean, ON, Canada). Reverse transcribed total RNA at 10-50 ng/pL
from each mouse was assayed in triplicate in 20 pL reactions using a two-step
quantitative real time-PCR (qRT-PCR) protocol. Gene-specific mRNA quantitation was
determined for all genes; (Aco, Srebp-1c, Pgc-1a, Cpt-1a) on an ABI Prism (model 7900
FIT) Sequence Detection System (Applied Biosystems, Streetsville, ON, Canada)
according to the manufacturer’s instructions. All primer probes sets were manufactured
by Taqman® Assays-on-Demand (Applied Biosystems) with the exception of Srebp-1c,
which is designed from the Mus musculus srebfl sequence (Genbank accession no.
AL669954), as described in Chapter 2 (11).
3.2.6 Adipocyte Quantitation
White adipose tissue (WAT) was fixed in 10% formalin, embedded in paraffin and
sectioned on a Microm FIM335E Microtome and stained with hematoxlyin and eosin.
Slides were cover-slipped using Cytoseal xylene-based mounting medium (Thermo
Scientific). All photomicrographs were generated on an Olympus BX50 microscope with
a Qlmaging Retiga EXi FAST camera (Qlmaging, Surrey, BC, Canada). Adipocyte
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diameter was calculated using Northern Eclipse 7.0 software on 20x magnification
photomicrographs.
3.2.7 Micro-CT Imaging
In a separate study, male C57BI/6 mice and Fgf21'/ mice on a C57BI/6
background, were fed ad libitum for four weeks (n=4-6/group) either chow, western or a
western diet supplemented with 3% wt/wt naringenin. Whole-body composition analysis
was conducted by micro-CT imaging using a GE locus Ultra micro-CT scanner. Non
fasted mice were anesthetized with 1.5% isoflurane in 0 2. A calibrating phantom,
comprising air and water was scanned concurrently to ensure images were
reconstructed equivalently. The scan protocol consisted of an x-ray tube voltage of 80
kVp and a current of 55.0 mA. In a scan time of 16 seconds, 1000 views were acquired
in one continuous rotation. Images were reconstructed to an isotropic voxel size of 150
pm3. Using the image values of water and air, data were calibrated into CT number,
expressed in Hounsfield Units (HU). The analysis was conducted by Micro View software
version 2.2. Adipose tissue was isolated using a threshold value window of -225 to -60
HU and the volume of adipose tissue was automatically calculated by MicroView as the
number of voxels falling within the threshold window multiplied by the voxel volume (150
pm3).The adipose tissue was highlighted in red. To measure visceral and subcutaneous
adipose volumes, contours were manually drawn around the thoracic and abdominal
cavities and a 3D region of interest (ROI) was generated. This enabled separate
calculation of the visceral adipose tissue volume within the ROI, and the subcutaneous
adipose tissue volume without.
3.2.8 Statistical Analysis
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Data is presented as the mean ± SEM. The statistical difference between mice of
the same genotype, fed chow, western, or western + 3% naringenin was determined by
a one-way analysis of variance (ANOVA) and post hoc Tukey test using Sigma Plot
version 14.0. Data with different letters are considered statistically different (P<0.05).
The statistical difference between mice of different genotype (WT vs. Fgf21v' mice), fed
the same diet, was determined by a Student’s unpaired t-test, using Sigma Plot version
14.0. Data with an asterisk (*) are considered statistically different (P<0.05).

3.3 Results
Naringenin prevents diet-induced obesity and adipocyte expansion in western-fed
WT and Fgf21'/' mice.
The administration of a high-fat, western diet to WT and Fgf21/' mice resulted in
a significant increase in diet-induced weight gain (WT and Fgf21'/', >4-fold), compared to
the respective chow-fed controls (Fig. 3-1 A). However, the absence of the FGF21 gene
increased body weight (1.6-fold), compared to WT animals fed the same western diet
(Fig. 3-1 A). Naringenin supplementation of the high-fat diet completely prevented the
diet-induced weight gain in WT and Fgf2T/ mice, to levels observed in chow-fed controls
(Fig. 3-1 A). No significant differences in caloric intake were observed among any of the
groups (Fig. 3-1B). The increased weight gain in western-fed Fgf21/ mice was primarily
due to enhanced visceral fat accumulation (1.3-fold), compared to western-fed WT mice
(Fig. 3-1C). Naringenin significantly attenuated adiposity by approximately 60% in both
WT and Fgf21'/' mice (Fig. 3-1C).
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Figure 3-1. Prevention of diet-induced obesity in WT and Fgf21/- mice by
naringenin. Male WT (C57BI/6) and Fgf21-/- mice were fed a chow diet, a western
(high-fat) diet, or a western diet supplemented with 3% naringenin for 16 weeks (n= 67/group). (A) Weight gain over 16 weeks (g). (B) Caloric intake expressed as
kcal/mouse/day. (C) Adiposity Index expressed as epididymal fat pad weight (g),
normalized to body weight (g). Values are the mean ± SEM. Different upper case
letters indicate statistical significance among WT animals (P <0.05). Different lower
case letters indicate statistical significance among Fgf21-/~mice (P <0.05). Asterisk (*)
indicates statistical significance between genotypes (WT vs Fgf21-/-)fed the same diet
(P <0.05).
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The deficiency of the FGF21 gene resulted in significantly increased mean
adipocyte diameter in epididymal fat from Fgf21'/' mice fed a chow or western diet (1.2fold for both), compared to WT mice fed the same diets (Fig. 3-2A). In contrast, the
addition of naringenin to western-fed WT or Fgf21'/' mice significantly attenuated
adipocyte diameter by 43 and 49%, respectively, compared to mice fed the western diet
alone (Fig.3-2A). The western diet shifted the peak of the adipocyte size distribution in
both WT and Fgf21'/' mice, such that a greater number of large adipocytes accumulated
in epididymal adipose tissue (Fig. 3-2B and C). However, the peak of the adipocyte
diameter distribution appeared to be exacerbated (shifted to the right) in western-fed
Fgf21/ mice (121-150 pm), compared to western-fed WT mice (91-120 pm) (Fig. 3-2B
and C). Naringenin-supplementation completely normalized the adipocyte diameter
distribution (31-91 pm), both in the presence, and absence of FGF21 (Fig. 3-2B and C).
Plasma FFA concentrations were unchanged by any of the dietary groups in WT mice.
Consistent with increased adipocyte hypertrophy in western-fed Fgf21'/' mice, circulating
FFA levels were significantly attenuated by 33% compared to western-fed WT mice,
suggesting that the liberation of FFA from adipose tissue is impaired in Fgf21'/' mice,
contributing to increased adipocyte size (Fig. 3-2D). Naringenin supplementation of the
western diet in Fgf21'/' mice restored plasma FFA to control levels (Fig. 3-2D).
Whole-body micro-CT imaging was conducted on a subset of WT and Fgf21'/'
mice fed chow, western or western + 3% naringenin for 4 weeks. The images revealed
that the western diet markedly increased adipose tissue volume compared to chow,
which was largely prevented by naringenin. Furthermore, for all three diets, Fgf21'/' mice
accumulated significantly more adipose tissue (red) throughout the entire body,

Figure 3-2. Prevention o f adipocyte expansion in W T and Fgf21/- m ice by
naringenin supplem entation to a w estern diet. Male WT (C57BI/6) and Fgf21~

mice were fed a chow diet, a western (high-fat) diet, or a western diet
supplemented with 3% naringenin for 16 weeks (n= 6-7/group). (A) Mean
adipocyte diameter (pm) in epididymal adipose tissue. (B) and (C) Adipocyte
diameter distribution, expressed as the percentage of total adipocytes counted,
versus the adipocyte diameter (pm), determined from photomicrographs of
hematoxylin and eosin-stained sections of epididymal adipose tissue (n= 100
adipocytes/treatment group). (D) Plasma free fatty acids (mmol/L). Values are
the mean ± SEM. . Different upper case letters indicate statistical significance
among WT animals (P <0.05). Different lower case letters indicate statistical
significance among F gf2t/1 mice (P <0.05). Asterisk (*) indicates statistical
significance between genotypes (WT vs Fgf21-/-) fed the same diet (P <0.05).
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compared to their WT counterparts (Fig. 3-3). Calculation of mean visceral and
subcutaneous

adipose

tissue

volume

demonstrated

that

all

mice

had

more

subcutaneous than visceral adipose tissue (approximately 2-fold) and that the western
diet increased the size of both tissue depots similarly (3- to 4-fold) (Fig. 3-4). Compared
to WT mice, Fgf21'/' mice demonstrated a 3.6- and 2.0-fold increase in visceral adipose
tissue volume when placed on a chow and western diet, respectively (Fig. 3-4A). A 2.2and 1.8-fold increase in subcutaneous adipose tissue volume was observed in chowand western-fed Fgf2V/~ mice, respectively, compared to WT animals (Fig. 3-4B). In
contrast, naringenin supplementation decreased both visceral and subcutaneous
adipose tissue volume by greater than 45% (Fig. 3-4).
Plasma lipid analysis in WT and Fgf21'/' mice.
The determination of plasma lipid concentrations in WT and Fgf21'/' mice
revealed only slight differences in plasma TG concentrations, due to the fact that both
genotypes of mice are on a C57BI/6 background and have no impairment of lipoprotein
clearance as in the Ldlr''' mouse strain. The western diet did not increase plasma TG in
either WT or Fgf21v' mice. Naringenin supplementation of the western diet attenuated
plasma TG in WT mice compared to chow (-30%), whereas naringenin had no effect on
plasma TG in Fgf21'/~ mice (Fig. 3-5A). Plasma cholesterol levels were significantly
increased in western-fed WT and Fgf21~/~ mice 2- to 2.5-fold, however naringenin
supplementation had no further effect in either genotype (Fig. 3-5B).
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Figure 3-3. Micro-CT images of fat distribution in WT and Fgf21A mice. In a
smaller study, male WT (C57BI/6) and Fgf21v- mice were fed a chow diet, a
western (high-fat) diet, or a western diet supplemented with 3% naringenin for 4
weeks (n= 6-7/group). Whole-body composition analysis was conducted by
micro-CT imaging using a GE locus Ultra micro-CT scanner. Mice were
anesthetized with 1.5% isoflurane in 0 2. Adipose tissue was isolated using a
threshold value window o f-225 to -60 HU and is highlighted in red.

150

Visceral Adipose Tissue Volume

A
81 [

WT
Fgf21-/*

3% Naringenin

B

Subcutaneous Adipose Tissue Volume

3% Naringenin
Figure 3-4. Reduction in visceral and subcutaneous adipose tissue volume in
WT and Fgf21/mmice by naringenin. In a smaller study, male WT (C57BI/6) and
Fgf21-A mice were fed a chow diet, a western (high-fat) diet, or a western diet
supplemented with 3% naringenin for 4 weeks (n= 4-6/group). (A) Visceral and (B)
subcutaneous adipose tissue volume (mm3 x 103) calculated from micro-CT images
generated using a GE locus Ultra micro-CT scanner. Values are the mean ± SEM.
Different upper case letters indicate statistical significance among WT animals (P
<0.05). Different lower case letters indicate statistical significance among Fgf21~/mice (P <0.05). Asterisk (*) indicates statistical significance between genotypes
(WT vs Fgf21-/- ) fed the same diet (P <0.05).
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Figure 3-5. Plasma lipid analysis in WT and Fgf21/- mice. Male WT (C57BI/6)
and Fgf21-/- mice were fed a chow diet, a western (high-fat) diet, or a western diet
supplemented with 3% naringenin for 16 weeks (n= 6-7/group). Plasma triglyceride
(A), and cholesterol (B) concentrations in mmol/L. Values are the mean ± SEM.
Different upper case letters indicate statistical significance among WT animals (P
<0.05). Different lower case letters indicate statistical significance among Fgf21-/mice (P <0.05). Asterisk (*) indicates statistical significance between genotypes
(WT vs Fgf21-/- ) fed the same diet (P <0.05).
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Naringenin prevents the development of hepatic steatosis and modulates hepatic
gene expression in western-fed WT and Fgf21'/' mice.
Significant hepatic steatosis developed in western-fed WT and Fgf21'/~ mice
compared to chow-fed controls (Fig. 3-6A-C). Although no differences were observed
between genotypes on the chow diet, there was a significant 1.9-fold increase in hepatic
CE and 2.6-fold increase in hepatic TG in western-fed mice lacking FGF21, compared to
western-fed WT mice (Fig. 3-6B and C). Addition of naringenin to the western diet in WT
mice decreased hepatic CE and TG (-76 and -71%, respectively) to levels observed in
chow-fed mice. Despite higher western diet-induced concentrations in Fgf21'/ mice,
naringenin supplementation completely normalized both hepatic CE and TG (-89 and 85%, respectively) (Fig. 3-6B and C).
In order to elucidate the mechanism through which naringenin alleviates the
hepatic lipid burden, the expression of key genes involved in regulating hepatic FA
oxidation and lipogenesis were analyzed by qRT-PCR. The expression of an important
transcriptional regulator of hepatic FA oxidation, Pgc-1a, was attenuated with western
feeding in WT (-36%) and Fgf21~/~mice (-47%) compared to chow-fed controls, although
the difference between genotypes was not significant (Fig. 3-7A).

Naringenin

supplementation significantly increased Pgc-1a expression in both WT and Fgf21'/' mice
by 33% and 40%, respectively compared to western-fed animals (Fig. 3-7A). The
western diet decreased the hepatic expression of a rate-limiting enzyme involved in
mitochondrial FA oxidation, Cpt-1a (-70 to -80%) in both genotypes (Fig. 3-7B).
Naringenin-supplementation significantly increased Cpt-1a mRNA in WT (63%) and
Fgf21v' (36%) mice compared to western-fed controls (Fig. 3-7B), although the genotype

Figure 3-6. Prevention of hepatic steatosis in western-fed WT and Fgf21-/mice treated with naringenin. Male WT (C57BI/6) and F g f2t/- mice were fed a
chow diet, a western (high-fat) diet, or a western diet supplemented with 3%
naringenin for 16 weeks (n= 6-7/group). Hepatic total cholesterol (A), cholesteryl
ester (B), and triglyceride concentrations (C) (pg/mg tissue weight). Values are the
mean ± SEM. Different upper case letters indicate statistical significance among
WT animals (P <0.05). Different lower case letters indicate statistical significance
among F gf2t/- mice (P <0.05). Asterisk (*) indicates statistical significance
between genotypes (WT vs Fgf21-A) fed the same diet (P <0.05).
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Figure 3-7. Modulation of hepatic gene expression in WT and Fgf21/- mice
supplemented with naringenin. Male WT (C57BI/6) and Fgf21/- mice were fed a
chow diet, a western (high-fat) diet, or a western diet supplemented with 3%
naringenin for 16 weeks (n= 6-7/group). Hepatic expression of Pgc-1a (A), Cpt-1 a
(B), Acox (C) and Srebp-1c (D) mRNA relative to Gapdh, determined by qRT-PCR
(n= 3-7/group). Values are the mean ± SEM. Different upper case letters indicate
statistical significance among WT animals (P <0.05). Different lower case letters
indicate statistical significance among Fgf21-/- mice (P <0.05). Asterisk (*) indicates
statistical significance between genotypes (WT vs Fgf21-/- ) fed the same diet (P
<0.05).
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difference was not significant. No diet-induced differences were observed in WT mice in
the expression of Acox, a regulator of peroxisomal FA oxidation. However, naringenintreatment of Fgf21/ mice significantly upregulated Acox mRNA compared to Fgf21~/~
mice fed the western diet alone (Fig. 3-7C). As anticipated, hepatic expression of the
lipogenic gene Srebp-1c was significantly increased (-60%) in both western-fed WT, and
Fgf2T/' animals (Fig. 3-7D). Naringenin supplementation normalized diet-induced Srebp1c expression both in the presence and absence of FGF21 (Fig. 3-7D).
Naringenin reduces ectopic lipid accumulation in muscle and improves glucose
homeostasis and insulin sensitivity in western-fed WT and Fgf21'/' mice.
Analysis of lipid accumulation in the quadriceps muscle revealed that Fgf21'/'
mice fed a western diet had a 2.7-fold increase in TG mass, compared to western-fed
WT animals (Fig. 3-8A). The exacerbation of muscle TG was prevented by greater than
50% with naringenin supplementation to the western diet in WT and Fgf21'/' mice (Fig. 38A). Western-feeding significantly increased fasting plasma insulin levels 3-fold in WT
animals and 9-fold in Fgf21v mice, compared to chow-fed controls (Fig. 3-8B). The
absence of the FGF21 gene significantly intensified fasting hyperinsulinemia almost 4
fold in western-fed mice, compared to western-fed WT animals (Fig. 3-8B). Naringenin
markedly attenuated plasma insulin by 75% and 88% in WT and Fgf21'/~ mice,
respectively (Fig. 3-8B). The mild, yet significant hyperglycemia that developed in
response to the western diet, compared to chow, was similar in WT and Fgf21'/' mice
(-11 vs. 8.5 mmol/L) (Fig. 3-8C). Naringenin supplementation completely prevented
hyperglycemia (8 mmol/L) in both genotypes (Fig. 3-8C).
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Figure 3-8. Prevention of muscle lipid accumulation, hyperinsulinemia and
mild hyperglycemia in western-fed WT and Fgf21/- mice treated with
naringenin. Male WT (C57BI/6) and Fgf21-/- mice were fed a chow diet, a western
(high-fat) diet, or a western diet supplemented with 3% naringenin for 16 weeks (n=
6-7/group). (A) Quadriceps triglyceride concentration (pg/mg tissue weight) (B)
Plasma insulin (ng/ml) was measured by ELISA. (C) Blood glucose (mmol/L) was
determined using a glucometer. Values are the mean ± SEM. Different upper case
letters indicate statistical significance among WT animals (P <0.05). Different lower
case letters indicate statistical significance among Fgf21/- mice (P <0.05). Asterisk
(*) indicates statistical significance between genotypes (WT vs Fgf21~/- ) fed the
same diet (P <0.05).
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To further assess glucose homeostasis, an oral GTT was conducted. Both
western-fed WT and Fgf21~/~mice demonstrated an impaired response to an exogenous
glucose load compared to their chow-fed counterparts (Fig. 3-9A and B). Although the
impairment in glucose tolerance in western-fed Fgf2T/' mice appeared to be greater than
observed in western-fed WT mice, no statistical significance between the two groups
was determined for the AUC (Fig. 3-9C). Naringenin supplementation to the western diet
in both genotypes completely restored the glucose excursion curves, such that the AUCs
were similar to chow-fed mice (Fig. 3-9A-C). A similar trend was observed following an
ITT. Fgf21'/' mice fed the western diet demonstrated an impaired response to exogenous
insulin compared to western-fed WT mice, although it failed to reach statistical
significance (P= 0.069) (Fig. 3-10). However, naringenin restored insulin sensitivity in
western-fed Fgf21'/'mice (Fig. 3-10).

3.4 Discussion
The function of FGF21 as a novel metabolic regulator has recently been
identified (16). FGF21 activates the coactivator molecule PGC-1a, thereby regulating
energy homeostasis and ketogenesis (7). Fgf21'/' mice fed a ketogenic diet, demonstrate
an impaired response to fasting, and have perturbations in glucose and lipid metabolism
(12). Provision of high-fat diets to C57BI/6 mice induces many of the components of the
metabolic syndrome including dyslipidemia, obesity, hyperinsulinemia and reduced
insulin sensitivity (17). Systemic administration of recombinant FGF21 to these mice
prevents obesity, reduces hepatic steatosis by inhibiting hepatic lipogenesis, and
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Figure 3-9. Improved glucose homeostasis in western-fed WT and Fgf21/- mice
treated with naringenin. Male WT (C57BI/6) and Fgf21-/- mice were fed a chow diet, a
western (high-fat) diet, or a western diet supplemented with 3% naringenin for 16 weeks
(n= 6-7/group). (A) and (B) Glucose tolerance tests (GTT) were performed after a 4-hour
fast by oral gavage of 20% glucose (1 g/kg body weight), with blood glucose
determinations at 0, 15, 30, 45, 60, 90 and 120 minutes post-gavage. (C) Absolute area
under the curve (AUC) in mmol/L x 120 minutes. Values are the mean ± SEM. Different
upper case letters indicate statistical significance among WT animals (P <0.05).
Different lower case letters indicate statistical significance among Fgf21-/- mice (P
<0.05). Asterisk (*) indicates statistical significance between genotypes (WT vs Fgf21-/-)
fed the same diet (P <0.05).
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Figure 3-10. Improved insulin sensitivity in western-fed WT and Fgf21/- mice
treated with naringenin. Male WT (C57BI/6) and F g f2t/- mice were fed a chow diet, a
western (high-fat) diet, or a western diet supplemented with 3% naringenin for 16 weeks
(n= 6-7/group). (A) and (B) Insulin tolerance tests (ITT) were performed in un-fasted mice
by i.p. injection of insulin (0.6 lU/kg body weight), with blood glucose determinations at 0,
15, 30, 45 and 60 minutes post-injection. (C) Absolute area under the curve (AUC) in
mmol/L x 60 minutes. Values are the mean ± SEM. Different upper case letters indicate
statistical significance among WT animals (P <0.05). Different lower case letters indicate
statistical significance among Fgf21v- mice (P <0.05). Asterisk (*) indicates statistical
significance between genotypes (WT vs Fgf21+) fed the same diet (P <0.05).
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improves insulin sensitivity (8,18). These beneficial effects are similar to the marked
metabolic protection induced by naringenin (11,15). Based on the known function of
FGF21, we predicted that deletion of the FGF21 gene in mice would worsen the
metabolic response to a high-fat diet. Furthermore, we hypothesized that the ability of
naringenin to prevent the metabolic dysregulation induced by a high-fat diet involves
activation of FGF21.
After 16 weeks of high-fat feeding, Fgf21'/' mice accumulated significantly more
adipose tissue compared to their WT counterparts. Conversely, naringenin prevented
the accelerated adiposity and enhanced adipocyte hypertrophy observed in western-fed
Fgf21'/' mice. Fgf21'/' mice fed the western diet developed significant hepatic steatosis,
with greater concentrations of hepatic TG and CE compared to WT animals. Naringenin
completely prevented hepatic steatosis in both genotypes through decreased expression
of genes involved in lipogenesis and enhanced expression of those regulating oxidation.
The western diet intensified hyperinsulinemia in Fgf21'/' mice, and delayed the response
to exogenous insulin. Naringenin normalized the elevated plasma insulin and restored
insulin sensitivity in western-fed WT and Fgf21'/' mice.
One of the most prominent phenotypes observed in high-fat fed Fgf21v' mice was
the enhanced adiposity (40%) in both subcutaneous and visceral fat depots and
adipocyte hypertrophy, compared to western-fed WT controls, despite no difference in
caloric consumption. This is similar to the finding by Badman et at. where Fgf21'/' mice
gained weight when fed a ketogenic diet compared to WT mice (12). The authors
proposed that the increased weight gain was due, in part, to the significantly attenuated
adipose tissue expression of adipose triglyceride lipase (ATGL), and hormone sensitive
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lipase (HSL) in Fgf21'/' mice , thereby preventing free fatty acid (FFA) lipolysis (12). This
prevention of lipolysis is consistent with the concept that FGF21 is upregulated in the
fasted state and activates adipose tissue lipolysis to release FFA for use in the liver (6).
In the current study, western-fed Fgf21/ mice also demonstrated significantly reduced
circulating FFA levels, compared to western-fed WT animals. Despite the increased
adiposity

in

western-fed

Fgf21''

mice,

naringenin

significantly attenuated

the

accumulation of adipose tissue, normalized adipocyte hypertrophy and prevented the
western-diet induced reduction in FFA concentrations. Analysis of the lipolytic genes
ATGL and HSL in adipose tissue may provide further insight into the mechanism of
protection against obesity conferred by naringenin.
Another striking phenotype observed in western-fed Fgf21'/' mice was the
exacerbated hepatic lipid accumulation. Although no differences in hepatic lipids were
observed between WT and Fgf21'A mice fed chow, high-fat feeding increased hepatic
TG and CE to a significantly greater extent (>50%) in Fgf21v mice, compared to WT
mice. These data are consistent with Fgf21'/' mice fed a ketogenic diet, in which hepatic
TG increased markedly (12), and with C57BI/6 mice injected with FGF21, which
prevented the development of diet-induced hepatic steatosis (8).
PGC- 1a and CPT- 1a are genes involved in the regulation of hepatic FA oxidation
(19), and PGC-1a is a known downstream target of FGF21 (7,20). Others have reported
that when fed a ketogenic diet, hepatic Pgc- 1a expression is significantly lower in Fgf21'
A mice (12). In the current studies, western-fed Fgf21A mice exhibited a modest,
although not significant, reduction in hepatic Pgc- 1a expression compared to WT mice
fed the same diet, which may be a contributing factor to the increased hepatic lipid
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accumulation. Although the western diet substantially decreased hepatic Cpt-1a mRNA,
no differences between genotypes were observed. A functional measurement of hepatic
FA oxidation would provide definitive evidence for decreased FA oxidation as a key
determinant of increased hepatic lipid accumulation in western-fed Fgf21/ mice.
Administration of recombinant FGF21 to obese mice prevented hepatic steatosis,
which was associated with reduced expression of TG and FA biosynthetic genes,
namely Acc and Fas (20). Although hepatic expression of Srebp1-c, which regulates
both Acc and Fas-mediated lipogenesis, was unaffected by FGF21 treatment, the
amount of the nuclear (active) SREBP-1c was attenuated, suggesting that FGF21
inhibits processing of SREBP-1c (20). In agreement with this finding, although the
western diet significantly increased hepatic Srebp1-c expression in both WT and Fgf2V/
mice compared to chow, no genotype difference was observed, despite substantially
greater plasma insulin levels in Fgf21'/' mice, compared to WT. Immunoblots for hepatic
nSREBPI and assays for FA synthesis would be required to determine if increased
nSREBPI-induced FA synthesis contributes to the marked TG accumulation in westernfed Fgf21'/' mice.
Despite the pronounced hepatic steatosis that developed in Fgf21'/' mice,
naringenin supplementation protected mice from CE and TG accumulation. Studies in
Chapter 2 demonstrated that naringenin supplementation to either a high-fat/highcholesterol (HFHC) or a low-fat/high-cholesterol (LFHC) diet significantly increased
hepatic Fgf21 expression (Chapter 2, Fig. 2-9.), along with Pgc-1a, Cpt-1a, and Acox. In
the current studies, naringenin significantly increased the expression of Pgc-1a, Cpt-1a,
and Acox in Fgf21'/' mice, despite the inability to increase hepatic Fgf21 expression,
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suggesting that naringenin does not require FGF21 to enhance the hepatic FA oxidation
program. Furthermore, FGF21 is regulated by PPARa (6), however luciferase reporter
assays in HepG2 cells demonstrated that naringenin fails to increase PPARa
transcription (data not shown). These data demonstrate that naringenin stimulates
hepatic FA oxidation in both an FGF21- and PPARa- independent mechanism.
The concept that the protective effect of naringenin is independent of direct
FGF21 activation is supported by differences in the regulation of hepatic gene
expression. Hepatic CpMcr mRNA is significantly increased by the addition of naringenin
to a western, HFHC or LFHC diet ((11), Chapter 2, Fig. 2-9). In contrast, in FGF21treated high-fat fed mice or in FGF21 transgenic mice, hepatic Cpt-1a mRNA is
unaffected (6,8). Instead, FGF21 transgenic mice have increased hepatic CPT-1a
protein levels (6). This suggests that naringenin confers control of Cpt-1 a transcription,
whereas FGF21 increases CPT-1 a protein through a post-transcriptional mechanism,
highlighting different mechanisms by which naringenin and FGF21 increase hepatic FA
oxidation. Naringenin exerts transcriptional control over hepatic Srebp-1c, as naringenin
markedly inhibits its expression in liver, whereas FGF21 injection appears to inhibit
SREBP-lc function through a post-transcriptional mechanism (8,12).
High-fat feeding in mice induces insulin resistance and hyperinsulinemia (11). In
this study, western-fed Fgf21'/' mice developed significant hyperinsulinemia and modest
insulin intolerance. The increased circulating insulin conferred control over plasma
glucose, as western-fed Fgf21v' mice did not display enhanced hyperglycemia or
glucose intolerance compared to western-fed WT mice. These data are consistent with
the notion that FGF21 has insulin-sensitizing effects. Administration of FGF21 to 3T3-L1
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adipocytes increases insulin-stimulated glucose uptake (9), and injection of recombinant
FGF21 attenuates hyperinsulinemia and glucose intolerance in high-fat fed mice (18).
Furthermore, FGF21 improves pancreatic p-cell function, as FGF21 treatment of
pancreatic islets from diabetic rodents increased glucose-induced insulin secretion, and
afforded protection from glucolipotoxicity and cytokine-induced apoptosis (21). In
contrast to the hyperinsulinemia observed in western-fed Fgf21'/~ animals, naringenin
treatment completely normalized plasma insulin, and improved glucose tolerance and
insulin sensitivity. In vitro studies in HepG2 hepatocytes show that naringenin is an
insulin-sensitizer, by activating the PI3-kinase and MAPKerk pathways independent of the
insulin receptor (22). Moreover, the markedly attenuated hepatic and muscle TG
accumulation, along with the marked reduction in adipose tissue, may have contributed
to the enhanced insulin sensitivity observed in naringenin-treated Fgf21'/' mice.
These studies clearly demonstrate that naringenin does not require FGF21 for its
effects. However the striking similarities between FGF21- and naringenin-treatment in
mice, including prevention of obesity and hepatic steatosis, and an insulin-sensitizing
effect (8,11,18), suggests that naringenin and FGF21 activate the same, or similar,
signaling mechanisms. Recently, it was reported that FGF21 acts directly on the liver of
C57BI/6 mice to activate MAPK signaling and increase the expression of downstream
ERK1/2 targets (20). In human HepG2 hepatocytes, naringenin treatment increases
ERK1/2 phosphorylation leading to a reduction in the downstream target microsomal
triglyceride transfer protein (MTP) (23,24). Therefore it is tempting to hypothesize that
naringenin can compensate for FGF21 deficiency, by activating the FGFR:(3-klotho
receptor complex or by directly activating similar downstream signaling cascades. In
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vitro studies involving the use of naringenin and recombinant FGF21 protein could reveal
a unique additive or synergistic relationship between these two factors.
It is also possible that naringenin mediates its effects through another FGF
molecule. FGF21 belongs to the “hormone-like” subgroup of FGFs that includes FGF19
(FGF15 in mice), FGF21 and FGF23 (25). All three FGFs lack the conventional FGF
heparin-binding domain allowing them to act in an endocrine-like manner (25). Of
interest, FGF19 transgenic mice have decreased adiposity, display enhanced insulin
sensitivity and have lower plasma glucose, TG and cholesterol levels (26), similar to
metabolic improvements observed in FGF21 transgenic animals (6,9). Administration of
recombinant FGF19 protein to ob/ob mice decreased body weight, improved glucose
tolerance and prevented hepatic TG accumulation (27). Furthermore, stimulation of 3T3L1 adipocytes with FGF19 also increases ERK1/2 phosphorylation (28). Therefore it is
possible that FGF19 and FGF21 share metabolic functions, and that naringenin
activates their receptors and/or signaling cascades, to achieve metabolic protection.
In conclusion, for the first time these studies provide in vivo evidence that in
response to a high-fat diet, FGF21 plays a key role regulating glucose and lipid
homeostasis. Furthermore, we show that the flavonoid naringenin can protect against
metabolic perturbations induced by high-fat feeding in the presence and absence of
FGF21, and therefore, does not require FGF21 to mediate is effects. However, these
studies highlight the possibility that naringenin may share similar signaling pathways as
the endocrine FGF molecules.
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CHAPTER 4
Discussion
4.1 Summary and Conclusions
With the incidence of cardiovascular disease and the metabolic syndrome rising
(1,2), the search for new preventative treatments is of significant interest. Natural
compounds known as flavonoids have increasingly been acknowledged for their health
benefits and their associations with disease prevention, including a reduced risk of
developing cardiovascular disease (3). The studies in this thesis utilize mouse models to
focus on physiological and pathophysiological responses to diets that contain high-fat, high
cholesterol, and high-carbohydrate, and their impact on components of the metabolic
syndrome including dyslipidemia, insulin resistance, inflammation, and atherosclerosis.
Furthermore, we have established that the citrus flavonoid naringenin can prevent the
metabolic dysfunction associated with cardiovascular disease. Figure 4-1 summarizes the
current understanding of the protective effects of naringenin determined by previous studies,
and from the work in this thesis.
Dietary cholesterol has been shown to be pro-inflammatory and may contribute to
the chronic-low grade inflammation associated with obesity and atherosclerosis (4-7).
Therefore, one aim of these studies was to determine the effect of naringenin-treatment to
mice fed diets that contain moderately high levels of cholesterol, and whether naringenin
could prevent the cholesterol-induced inflammatory response. It was also important to
establish if the protection against metabolic dysregulation conferred by naringenin only
occurs in the presence of dietary fat, therefore a low-fat, high-cholesterol diet was used to
induce atherosclerosis
The studies in Chapter 2 build on previously published data that shows that in mice
fed a high-fat diet, naringenin potently lowers lipids and prevents the dyslipidemia
associated with insulin resistance, thereby attenuating the development of atherosclerosis

Figure 4-1. Summary of the effects of naringenin in a mouse model of the
metabolic syndrome. In LdlrA mice fed either a HF, HFHC or LFHC diet,
naringenin does not impact caloric intake or lipid absorption in the intestine. In
the liver, naringenin prevents apoB100 secretion by reducing SREBP-1cmediated lipogenesis and increasing fatty acid oxidation. The reduction in
hepatic lipid accumulation by naringenin attenuates TG and cholesterol
secretion into the plasma leading to suppressed delivery of fatty acids to
adipose and muscle. Naringenin improves insulin sensitivity and increases
glucose uptake in muscle, resulting in correction of hyperinsulinemia and
hyperglycemia.
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subcutaneous and visceral depots, are prevented by naringenin. Whole-body
energy expenditure is enhanced by naringenin. Naringenin also prevents
cholesterol-induced inflammation in adipose tissue and liver, reduces systemic
inflammation and completely attenuates the inflammatory response at the level
of the arterial wall. Collectively, these improvements or corrections of metabolic
indices lead to a marked reduction in atherosclerosis. The effect of naringenin
in other tissues including the intestine, heart, pancreas and central nervous
system, among others, requires further study. Previous studies established the
protective effects of naringenin in high-fat fed animals. The experiments in this
thesis clearly demonstrate that the protection afforded by naringenin extend to
mice in which the metabolic insult is exacerbated by (a) the addition of
cholesterol to a high-fat diet or (b) by the addition of cholesterol to a highsucrose (low-fat) diet or by (c) the administration of a high-fat diet to mice
deficient in FGF21. Parameters in bold indicate the novel preventative effects
of naringenin discovered by the work in this thesis.
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(8,9). The current studies demonstrate that even in the presence of increased dietary
cholesterol, naringenin prevents hepatic steatosis through a reduction in Srebp-1c-mediated
lipogenesis. Naringenin also shifts the liver to an enhanced “fat burning” state by increasing
the genes that mediate hepatic fatty acid (FA) oxidation. However, naringenin does not alter
the cholesterol absorption in the intestine, and therefore must reduce hepatic and plasma
cholesterol levels via another mechanism. For the first time these studies demonstrate that
naringenin markedly upregulates the expression of hepatic Cyp7a1, thereby possibly
converting excess hepatic cholesterol into bile acids. Further studies will aid in defining the
mechanism through which naringenin impacts Cyp7a1 expression.
The reduction in hepatic lipid load by naringenin decreased the lipid availability for
apoB100 production from the liver of cholesterol-fed animals. This builds on previous in vitro
findings that showed that naringenin reduces apoB100 secretion from HepG2 hepatocytes
(10-13). The naringenin-induced reduction in cholesterol and TG content of circulating VLDL
and LDL particles in plasma attenuated hypertriglyceridemia and hypercholesterolemia.
Furthermore, this prevention of dyslipidemia by naringenin limited lipid availability for ectopic
accumulation in adipose tissue.
A novel aspect of these studies is the ability of naringenin to prevent the
inflammatory response associated with cholesterol feeding. Diets that contain either high- or
low-fat with added cholesterol induced the expression of inflammatory mediators in the liver
and adipose tissue, contributing to an enhanced state of systemic inflammation. In
comparison, naringenin treatment prevented lipid accumulation in the liver, thereby reducing
cholesterol- and FA-induced hepatic insult and contributing to a significant reduction in
hepatic inflammation. Furthermore, the prevention of weight gain and concomitant reduction
in adipocyte hypertrophy with naringenin was associated with reduced adipose tissue
inflammation. Together, the naringenin-induced attenuation of metabolic stress in the liver
and adipose tissue, and the in vitro data establishing naringenin as an insulin-sensitizer
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(10), collectively may have contributed to naringenin’s ability to improve glucose tolerance
and insulin insensitivity.
The overall improvement in metabolic functioning with naringenin, including a
reduction in hepatic steatosis and circulating lipids, along with decreased inflammation and
insulin resistance, contributed to a protection from atherosclerotic lesion development.
These studies demonstrate that cholesterol-feeding in Ldlrv' mice induces significant
accumulation of cholesterol and TG in the aorta, which is associated with the formation of
complicated lipid-laden, fibrotic lesions. However, treatment with naringenin prevents the
cholesterol-induced progression of lesions to an advanced stage. It is possible that
naringenin attenuates lipid deposition in the aorta by reducing the formation of macrophage
foam cells, as evidenced by decreased lipid accumulation in peritoneal macrophages. For
the first time, these studies demonstrate that naringenin prevents aortic inflammation and
the abundance of inflammatory markers in peritoneal macrophages, demonstrating that
naringenin’s anti-inflammatory property extends to the artery wall, and may be another
mechanism by which naringenin prevents the progression of atherosclerosis.
In light of the beneficial metabolic effects induced by naringenin-treatment (Chapter 2
and (8,9)), it was important to delineate naringenin’s mechanism of action. When
administered to high-fat fed mice, FGF21 has many beneficial effects that are similar to
naringenin, including a prevention of obesity, hepatic steatosis, dyslipidemia, and insulin
resistance (8,14). Naringenin also upregulates the expression of Fgf21 in the liver (Chapter
2, Fig. 2-9). Therefore we hypothesized that naringenin may, in part, require FGF21 for its
preventative effects. However, the studies in Chapter 3 demonstrate for the first time that
although the absence of FGF21 exacerbates the response to high-fat feeding in mice,
naringenin compensates for the loss of FGF21 by correcting the metabolic complications
associated with feeding the western diet. These studies confirm that naringenin does not
require FGF21 to mediate its metabolic effects. Additional evidence is required to determine
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if naringenin utilizes another FGF (FGF19) or directly stimulates an FGF receptor/(3-Klotho
complex. However, it is possible that naringenin may have multiple targets and does not
have a unique mono-mechanism.
4.2 Future Directions
The studies in this thesis build on previously published data elucidating the
therapeutic potential of the citrus flavonoid naringenin. However, further detailed in vitro and
in vivo studies will identify naringenin’s main molecular target and will contribute to the
understanding of naringenin’s mechanism of action. Furthermore, such studies will aid in the
discovery of new molecules that modulate insulin signaling, lipid lowering and energy
homeostasis.
Perhaps one of the most interesting findings from the studies involving naringenin
supplementation to cholesterol-fed mice is the prominent increase in hepatic Cyp7a1
abundance. Currently, studies are underway in cholesterol-fed Ldlrv' mice to assess the
difference, if any, in the accumulation of bile acids and cholesterol in the gall bladder with
naringenin treatment. Furthermore, the effect of naringenin treatment in cholesterol-loaded
human HepG2 hepatocytes could elucidate if naringenin mediates the pathways involved in
Cyp7a1 regulation in a direct or indirect manner.
Another important finding from these studies is the ability of naringenin to prevent the
cholesterol induced inflammatory response. In vitro studies have demonstrated that
naringenin prevents inflammation in human airway epithelial cells (15). However, the ability
of naringenin to prevent inflammatory signaling in the infiltrating macrophage, or in the
macrophage foam cell, has not been determined. The use of human THP-1 monocytes or
mouse J774A.1 macrophages, loaded with cholesterol and/or TG, may help to elucidate the
mechanism through which naringenin mediates lipid uptake, cholesterol efflux, FA oxidation
and inflammatory signaling at the level of the macrophage.
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In Chapter 3, the role of FGF21 in mediating the response to high-fat feeding is
clearly established. Recombinant FGF21 protein has been shown to reduce plasma
cholesterol and TG, and reverse hepatic steatosis when administered to high-fat fed mice
(14). Flowever, the role of FGF21 in regulating apoB100 secretion from the liver has not
been identified. HepG2 cells express FGF receptors (FGFR) 1-4, (3-Klotho and FGF21
(16,17). Therefore, studies involving HepG2 cells could assess the ability of recombinant
FGF21 protein to enhance FA oxidation and inhibit apoB100 secretion. Increased apoBIOOcontaining particles in the plasma are a risk factor for atherosclerosis (18). Therefore,
breeding

Fgf2T/

mice onto the Ld/r7' strain, which is susceptible to developing

atherosclerosis (19), would determine if the absence of FGF21 confers increased
susceptibility to atherosclerosis.
From the studies in Chapter 3, it is clear that naringenin does not require FGF21 to
mediate its preventative effects. However, it is possible that naringenin and FGF21 utilize
similar signaling pathways or receptors. Therefore, administration of both FGF21 and
naringenin to lipid-loaded HepG2 cells may reveal an additive or synergistic relationship,
whereby lipid-lowering and FA oxidation are enhanced in the presence of both factors
compared to one factor alone. If these studies are positive, they could be extended in vivo,
whereby high-fat fed FGF21 transgenic animals are treated with naringenin to assess the
magnitude of the preventative effect. These proposed studies may highlight a unique
relationship between naringenin and FGF21.
In conclusion, naringenin prevents metabolic dysrégulation induced by cholesterol
feeding in mice. Moreover for the first time, detailed in vivo studies have demonstrated the
potent anti-inflammatory capacity of naringenin, and the implications this may have on
preventing metabolic disease including atherosclerosis. Although we have established that
naringenin does not require FGF21 to potentiate its response, future studies must be
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conducted to determine the mechanism of action by which naringenin alleviates metabolic
dysfunction.
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